[{"text": "PREMIUM Guidewire Software to Join S&P MidCap 400, Arrowhead Pharmaceuticals to Move to S&P SmallCap 600 MT Newswires Thu, Jan 23, 2025, 1:50 PM In This Article: GWRE +0.67% ARWR -5.73% APO-PA -1.57% Guidewire Software (GWRE) will replace Arrowhead Pharmaceuticals (ARWR) in the S&P MidCap 400, as th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-23T10:50:56+00:00", "sentiment": {"score": 0.07379053253680468, "confidence": 0.08348322659730911, "probabilities": {"positive": 0.08348322659730911, "negative": 0.009692694060504436, "neutral": 0.9068241119384766}}, "embedding": [-0.24644339084625244, -0.207520991563797, 0.05115094408392906, 0.01700984686613083, 0.3349919319152832, 0.04834336042404175, 0.005589695647358894, 0.23457014560699463, -0.11517122387886047, 0.001859597978182137, 0.014773626811802387, 0.3219181299209595, 0.01098265964537859, 0.07743437588214874, -0.025483472272753716, -0.0679246112704277, 0.024804387241601944, -0.13776685297489166, 0.12519587576389313, -0.049253854900598526, -0.13754230737686157, -0.10016727447509766, 0.04716372862458229, -0.003439683699980378, 0.09506551921367645, 0.0500730536878109, -0.12884332239627838, 0.053931012749671936, -0.13863147795200348, -0.0841265544295311, -0.13984249532222748, -0.06271909922361374, 0.13829024136066437, -0.07557661831378937, -0.001745502813719213, 0.0014365458628162742, -0.04535406827926636, 0.11536365747451782, -0.0885702520608902, -0.10678953677415848, 0.052504852414131165, -0.13377541303634644, -0.1422387808561325, 0.046064868569374084, 0.08407235145568848, -0.056182246655225754, -0.09767188876867294, 0.05206407234072685, 0.006483528297394514, 0.11455957591533661, 0.061199769377708435, -0.2526123821735382, -0.05039716139435768, -0.03817775845527649, 0.020090529695153236, 0.010955046862363815, -0.18984876573085785, -0.22121402621269226, -0.02841205522418022, -0.06540503352880478, -0.08338791877031326, -0.13850058615207672, -0.19467255473136902, 0.19869278371334076, -0.011099724099040031, 0.17993073165416718, 0.25303003191947937, 0.21483346819877625, 0.003397025167942047, -0.16978703439235687, -0.14605794847011566, 0.13071200251579285, -0.006892743986099958, 0.11870687454938889, 0.07791239023208618, 0.12606951594352722, 0.07605882734060287, 0.04025941714644432, 0.1462191790342331, 0.008576588705182076, -0.000953985785599798, 0.09439972788095474, -0.022850312292575836, 0.020350735634565353, 0.008996563032269478, 0.043803758919239044, -0.032125119119882584, -0.056782566010951996, -0.0717107430100441, -0.2135099321603775, 0.1071091964840889, 0.028517572209239006, -0.012679563835263252, -0.031442124396562576, -0.14483563601970673, 0.1489233523607254, -0.18095149099826813, -0.16365541517734528, -0.21237695217132568, 0.04662352055311203, -0.035061851143836975, -0.07852114737033844, -0.16855815052986145, -0.20668524503707886, 0.11645784974098206, -0.14194880425930023, 0.04404491186141968, 0.1509885936975479, 0.06642722338438034, 0.1280454844236374, -0.06206195056438446, 0.07046051323413849, 0.008641491644084454, -0.2625212073326111, 0.0078060682862997055, 0.0981372520327568, -0.20829671621322632, 0.11116896569728851, 0.16572827100753784, 0.006433720234781504, -0.1373237818479538, 0.13891416788101196, -0.012693303637206554, -0.05573664605617523, 0.013372298330068588, 0.006660798564553261, -0.04491735249757767, 1.407980097044867e-32, -0.04135113209486008, 0.21995356678962708, -0.03737436980009079, -0.07414498925209045, 0.02040567807853222, -0.002541405614465475, 0.03957025334239006, -0.07838026434183121, -0.24454334378242493, 0.04955284669995308, -0.1574425846338272, 0.06902609765529633, -0.19723418354988098, 0.0877501592040062, -0.02815026417374611, -0.1539468765258789, 0.022259265184402466, 0.1856038123369217, 0.12266823649406433, -0.06308494508266449, -0.0320170521736145, -0.040610067546367645, 0.049896273761987686, -0.018691612407565117, 0.022490721195936203, 0.2866300940513611, 0.10614120960235596, 0.008221958763897419, 0.28521251678466797, 0.10762035101652145, -0.15478630363941193, 0.1599351316690445, -0.009516583755612373, -0.10009108483791351, -0.11771028488874435, -0.040192898362874985, -0.2707599699497223, -0.20187115669250488, 0.03715164214372635, -0.10114628076553345, 0.003028734354302287, 0.034506380558013916, -0.21236848831176758, -0.08353599905967712, 0.0748642310500145, 0.0023719496093690395, 0.060682203620672226, -0.0005054023931734264, 0.10932890325784683, 0.035096440464258194, -0.07689806073904037, 0.02602691389620304, -0.11375944316387177, 0.10900721698999405, -0.07924051582813263, 0.04081317037343979, -0.01841096766293049, -0.012477926909923553, 0.2013491988182068, -0.015973201021552086, 0.22845955193042755, 0.1719864010810852, 0.06982475519180298, -0.09017923474311829, -0.0064018587581813335, 0.11268709599971771, -0.049146607518196106, -0.08603617548942566, -0.09148403257131577, 0.2039431780576706, 0.08680261671543121, -0.1327313780784607, 0.07676690816879272, 0.20218752324581146, -0.021765880286693573, -0.04367513954639435, -0.01705262064933777, 0.17934861779212952, 0.20646534860134125, 0.014866913668811321, -0.1305767297744751, 0.009197545237839222, 0.10699424892663956, 0.22630517184734344, 0.04892353340983391, -0.07303620129823685, 0.16908176243305206, -0.04826200008392334, -0.05332503467798233, 0.13158532977104187, 0.061406977474689484, -0.004500675015151501, -0.1362951397895813, 0.19891457259655, -0.014612880535423756, -1.2323622695895743e-32, 0.011277110315859318, 0.014760080724954605, 0.0946749746799469, -0.13146302103996277, -0.2647787928581238, -0.06122270226478577, 0.004979935474693775, 0.07949426025152206, 0.26335448026657104, 0.1672016978263855, 0.06553419679403305, 0.07344011962413788, -0.1830117553472519, -0.05391981080174446, 0.03654002398252487, -0.10385359078645706, 0.08360078185796738, -0.21292106807231903, -0.030737439170479774, 0.02091922238469124, 0.01387766283005476, 0.07875476777553558, -0.123638816177845, 0.11757037043571472, 0.19126608967781067, -0.12180837988853455, 0.23352497816085815, 0.22265823185443878, -0.03439193591475487, -0.07822072505950928, 0.03034742921590805, 0.00610947422683239, -0.1689673811197281, -0.00423467205837369, -0.09825893491506577, -0.04141659662127495, 0.21825747191905975, 0.13798509538173676, -0.05651172250509262, -0.09640015661716461, 0.2414117008447647, -0.09611470997333527, -0.06962008774280548, -0.08916711062192917, 0.0765836089849472, -0.0034140965435653925, 0.003954106941819191, -0.08484657108783722, 0.06685451418161392, -0.10619611293077469, -0.059363216161727905, -0.03118244558572769, 0.13595379889011383, -0.1263427436351776, -0.09969137609004974, 0.03163304552435875, 0.07246467471122742, -0.0220966599881649, -0.045305684208869934, -0.2322571873664856, 0.012114126235246658, 0.06583531200885773, -0.09271412342786789, 0.02935216575860977, 0.02067740634083748, 0.10601678490638733, 0.20956213772296906, -0.25052523612976074, -0.09534554183483124, -0.0026327897794544697, -0.11867117136716843, -0.07278421521186829, 0.14176467061042786, -0.2250591367483139, 0.10852454602718353, 0.08867738395929337, -0.030709093436598778, 0.02965245209634304, -0.073646180331707, -0.1678263396024704, 0.051351241767406464, -0.03010696917772293, -0.11971165239810944, 0.041985608637332916, -0.0428023599088192, -0.10617677122354507, 0.20427793264389038, -0.04719492793083191, 0.06007824093103409, 0.018016329035162926, -0.2081894874572754, -0.04263196885585785, -0.07824523746967316, 0.11773447692394257, 0.009117809124290943, -9.977624415569153e-08, 0.08062281459569931, 0.12433603405952454, -0.01831996627151966, 0.018888285383582115, 0.05340445041656494, 0.1384829431772232, -0.021597251296043396, 0.03121872805058956, -0.025875959545373917, 0.13415510952472687, 0.02089923620223999, 0.03387467563152313, -0.11684634536504745, 0.007436180021613836, -0.025089411064982414, 0.06412424147129059, 0.01863379403948784, 0.038764361292123795, -0.0687674954533577, -0.13204124569892883, -0.08475328236818314, 0.18299755454063416, 0.1511375606060028, -0.001876346068456769, 0.08736203610897064, -0.054564736783504486, 0.16114641726016998, 0.09845580160617828, 0.15243913233280182, -0.04416311904788017, -0.03914594277739525, 0.02723037265241146, -0.17138761281967163, 0.10958097875118256, 0.01227794773876667, -0.011572674848139286, -0.06638006865978241, 0.17729103565216064, 0.032887134701013565, 0.19810804724693298, 0.02933882735669613, -0.0593930222094059, 0.02418900839984417, 0.008063512854278088, -0.1290973573923111, 0.0438653938472271, -0.14354479312896729, -0.04305827617645264, 0.2187572568655014, 0.03608061373233795, 0.08317872881889343, -0.07915084064006805, -0.05915996432304382, -0.0847216546535492, -0.07980255782604218, 0.06650856882333755, 0.16714057326316833, -0.31602081656455994, -0.1381663680076599, -0.05474644899368286, 0.050028424710035324, -0.3027956485748291, 0.12283361703157425, 0.07942976802587509], "changes": {"1wk": -7.338596717677241}}, {"text": "Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 PR Newswire Thu, Jan 23, 2025, 1:54 AM 2 min read In This Article: APO -2.26% APO-PA -1.57% ARWR -5.73% GWRE +0.67% B +0.04% NEW YORK , Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE: GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE: B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27 . S&P 500 constituent Apollo Global Management Inc. (NYSE: APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewire Software GWRE Information Technology January 27, 2025 S&P MidCap 400 Deletion Arrowhead Pharmaceuticals ARWR Health Care January 27, 2025 S&P SmallCap 600 Addition Arrowhead Pharmaceuticals ARWR Health Care January 27, 2025 S&P SmallCap 600 Deletion Barnes Group B Industrials For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500\u00ae and the Dow Jones Industrial Average\u00ae. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets. S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com . FOR MORE INFORMATION: S&P Dow Jones Indices index_services@spglobal.com Media Inquiries spdji.comms@spglobal.com Cision View original content: https://www.prnewswire.com/news-releases/guidewire-software-set-to-join-sp-midcap-400-arrowhead-pharmaceuticals-to-join-sp-smallcap-600-302357962.html SOURCE S&P Dow Jones Indices View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-22T22:54:00+00:00", "sentiment": {"score": 0.04613961558789015, "confidence": 0.059445593506097794, "probabilities": {"positive": 0.059445593506097794, "negative": 0.013305977918207645, "neutral": 0.9272484183311462}}, "embedding": [-0.13080830872058868, -0.21635720133781433, -0.0471610426902771, 0.09178803116083145, 0.10977618396282196, 0.01368064247071743, 0.06849218159914017, 0.03519563376903534, -0.010285835713148117, 0.02130429819226265, -0.05234600976109505, 0.3298802375793457, -0.10821110010147095, 0.018845587968826294, -0.1389738768339157, -0.013431199826300144, -0.03617197275161743, -0.02539553865790367, 0.027515558525919914, 0.07431900501251221, -0.013019900768995285, -0.12217626720666885, -0.01485392451286316, 0.008563708513975143, -0.11742521822452545, 0.07341796159744263, -0.08071048557758331, 0.016866199672222137, -0.19979359209537506, -0.03074692189693451, -0.08148714900016785, 0.13972976803779602, 0.07647030055522919, -0.017614101991057396, -0.08949132263660431, 0.14337283372879028, 0.07340575754642487, 0.05112467706203461, 0.19955337047576904, -0.059845831245183945, 0.07744540274143219, -0.05945706367492676, -0.1447559893131256, -0.060489580035209656, 0.03467443585395813, -0.031258996576070786, -0.06453157961368561, 0.05338285490870476, -0.03288867697119713, 0.019874487072229385, -0.12816715240478516, -0.09309256076812744, -0.1032896637916565, -0.034275785088539124, -0.003206128254532814, -0.009317044168710709, -0.16907525062561035, -0.16373223066329956, 0.012323932722210884, -0.05168090760707855, -0.01739901676774025, -0.032499466091394424, -0.0011409595608711243, 0.1251518875360489, 0.14800900220870972, 0.03106520138680935, 0.18464156985282898, -0.0027085058391094208, -0.04818055033683777, -0.09246359765529633, 0.009559120051562786, 0.02626599743962288, -0.10563384741544724, 0.08494593948125839, -0.07797844707965851, 0.06749673187732697, 0.03701641038060188, 0.05115404725074768, 0.14500582218170166, -0.11784470081329346, -0.02273104153573513, 0.07546300441026688, 0.056246645748615265, 0.0020313216373324394, -0.08665162324905396, -0.011885376647114754, 0.010550674982368946, 0.08631151914596558, 0.0840223953127861, -0.20617935061454773, 0.06228110194206238, -0.033609360456466675, -0.10152673721313477, -0.023144608363509178, 0.12174025177955627, 0.031998757272958755, -0.0868496298789978, 0.03536596521735191, 0.041447579860687256, -0.005870550870895386, 0.030732324346899986, 0.06494081765413284, -0.1385924071073532, -0.10991585999727249, -0.011729932390153408, -0.07039950042963028, 0.009553413838148117, -0.028448328375816345, 0.0655328631401062, 0.07138141244649887, -0.19686682522296906, 0.25239840149879456, -0.07624569535255432, -0.22758108377456665, -0.09162646532058716, 0.020061420276761055, -0.11403177678585052, 0.05682618170976639, 0.21851933002471924, 0.021772976964712143, 0.014209949411451817, 0.19949382543563843, -0.13405855000019073, -0.038225188851356506, -0.03342852741479874, 0.08471469581127167, -0.23686134815216064, 1.2008964164015725e-32, 0.007878593169152737, 0.1153385192155838, 0.07124140858650208, -0.06294756382703781, -0.10303207486867905, 0.05021626502275467, 0.10923153162002563, -0.10243210941553116, -0.13332468271255493, 0.11182810366153717, -0.2995225787162781, 0.10221037268638611, -0.0732044130563736, 0.05529216304421425, 0.050906624644994736, -0.11702761799097061, 0.021016700193285942, 0.07264292240142822, 0.13825088739395142, -0.2025538980960846, -0.05054638907313347, 0.09697158634662628, -0.06418545544147491, 0.0816236212849617, 0.09700460731983185, 0.1796657294034958, -0.04586336761713028, -0.019093304872512817, 0.04854828119277954, 0.09485913068056107, 0.04635348170995712, 0.035107240080833435, -0.11941346526145935, -0.09286069124937057, -0.0736849308013916, -0.08464448153972626, -0.19340470433235168, -0.04943932965397835, -0.005436837673187256, -0.09528692066669464, 0.031419020146131516, 0.09516456723213196, -0.1535535454750061, -0.09773080796003342, -0.08525217324495316, 0.04001379385590553, -0.0978655070066452, 0.04170474410057068, 0.08450955152511597, -0.024746965616941452, -0.1770264208316803, -0.012301747687160969, 0.06225457414984703, 0.05212508514523506, -0.11767745018005371, 0.024420887231826782, 0.07335452735424042, -0.11899873614311218, 0.029528480023145676, 0.13795506954193115, -0.017721008509397507, 0.177221417427063, -0.035714611411094666, 0.007587585598230362, -0.050748176872730255, 0.18754303455352783, 0.11858077347278595, 0.11738981306552887, -0.05818081274628639, 0.15378955006599426, -0.031752850860357285, 0.0342220813035965, 0.20019972324371338, 0.04724114015698433, 0.01872728019952774, -0.05878971517086029, 0.11388395726680756, 0.135362446308136, 0.08819575607776642, -0.054075099527835846, -0.08559656143188477, 0.06762589514255524, 0.12486603856086731, 0.09246087074279785, -0.02201433852314949, -0.1477142572402954, 0.08246031403541565, 0.07351785898208618, -0.08338955044746399, -0.06497563421726227, -0.009589962661266327, -0.014946606941521168, -0.003168240189552307, 0.12332334369421005, -0.03794318810105324, -1.3035168528231674e-32, -0.0018337182700634003, -0.062077611684799194, 0.023640815168619156, -0.08108779042959213, -0.17316925525665283, -0.05646078288555145, 0.25118550658226013, -0.0983159989118576, 0.09997723996639252, -0.028119798749685287, -0.05573355779051781, 0.01898491196334362, -0.0682889074087143, -0.010078972205519676, -0.05798163264989853, 0.06614185124635696, -0.07625977694988251, -0.06463980674743652, -0.014822915196418762, 0.048046521842479706, 0.09693500399589539, 0.19283455610275269, -0.06511210650205612, 0.1447914093732834, 0.09271356463432312, -0.0379110611975193, 0.1627020537853241, 0.06354930996894836, -0.058396127074956894, 0.013975701294839382, -0.046879224479198456, -0.1580270379781723, -0.1524050086736679, 0.14318883419036865, -0.07034364342689514, -0.06984444707632065, -0.024155432358384132, -0.06874055415391922, -0.02367166429758072, -0.011561237275600433, 0.11215020716190338, 0.11201653629541397, 0.07973812520503998, 0.08835810422897339, 0.12770840525627136, 0.08813215047121048, 0.04509708285331726, -0.0006960548926144838, 0.05212407559156418, -0.07732649147510529, -0.1980861872434616, 0.07743096351623535, 0.07668636739253998, -0.044045839458703995, -0.03346242383122444, -0.01467856578528881, -0.0117463618516922, -0.007091963663697243, -0.21069201827049255, -0.15760603547096252, -0.02959008887410164, 0.09949018061161041, 0.02313731610774994, 0.15837883949279785, 0.06650452315807343, 0.06510788202285767, 0.011097822338342667, -0.31159377098083496, -0.027481159195303917, -0.22266197204589844, 0.008572296239435673, -0.10468947142362595, 0.051970429718494415, -0.17168506979942322, -0.05404345691204071, 0.07973892986774445, -0.10192759335041046, -0.012261377647519112, -0.098251573741436, 0.09468422085046768, 0.12477876991033554, 0.04772841930389404, -0.11552196741104126, 0.10008180141448975, -0.02604850009083748, 0.15433335304260254, 0.059954676777124405, -0.00658534187823534, 0.003081291913986206, -0.11014237999916077, -0.09666474163532257, -0.07080216705799103, 0.01878391206264496, 0.0450325533747673, -0.09183455258607864, -9.952879764796307e-08, 0.012422317638993263, -0.007406769320368767, 0.05468503013253212, -0.030004356056451797, 0.15734323859214783, -0.0006166608072817326, -0.04301328957080841, 0.08129937946796417, -0.021961485967040062, 0.18765424191951752, 0.24975371360778809, 0.05601242184638977, -0.19991055130958557, -0.006368614733219147, -0.055098310112953186, -0.10051722824573517, -0.20758509635925293, 0.013996010646224022, -0.03537716716527939, -0.11085163801908493, -0.07582592964172363, 0.13980036973953247, 0.14841072261333466, 0.023849692195653915, 0.1980559229850769, -0.03420683741569519, 0.050280503928661346, -0.08397986739873886, 0.06591170281171799, 0.08374341577291489, 0.052280694246292114, -0.02016349881887436, -0.009853517636656761, 0.07667271047830582, 0.07235665619373322, 0.008843602612614632, 0.10163803398609161, 0.23569577932357788, 0.09482906758785248, 0.18036200106143951, -0.050875578075647354, -0.09395013749599457, 0.04367610067129135, -0.010583113878965378, 0.03358645737171173, 0.026189176365733147, -0.2239513099193573, 0.09912358224391937, 0.19106566905975342, -0.0892132818698883, -0.0014389539137482643, -0.0936104953289032, -0.07096722722053528, -0.04538285732269287, -0.07635991275310516, 0.1003815159201622, -0.0946611762046814, -0.07988670468330383, -0.03497789055109024, -0.11521677672863007, 0.10864068567752838, -0.15210050344467163, -0.0338703915476799, 0.14846619963645935], "changes": {"1wk": 1.2176645845502239}}, {"text": "Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results Business Wire Thu, Jan 23, 2025, 12:00 AM 2 min read In This Article: ARWR -5.73% PASADENA, Calif., January 22, 2025 --( BUSINESS WIRE )--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3 . Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead\u2019s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com , or follow us on X (formerly Twitter) at @ArrowheadPharma , LinkedIn , Facebook , and Instagram . To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as \"may,\" \"will,\" \"expect,\" \"believe,\" \"anticipate,\" \"hope,\" \"intend,\" \"plan,\" \"project,\" \"could,\" \"estimate,\" \"continue,\" \"target,\" \"forecast\" or \"continue\" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Story Continues Source: Arrowhead Pharmaceuticals, Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20250122095610/en/ Contacts Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 ir@arrowheadpharma.com Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com Media: LifeSci Communications, LLC Kendy Guarinoni, Ph.D. 724-910-9389 kguarinoni@lifescicomms.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-22T21:00:00+00:00", "sentiment": {"score": 0.011730894446372986, "confidence": 0.030273541808128357, "probabilities": {"positive": 0.030273541808128357, "negative": 0.01854264736175537, "neutral": 0.9511837959289551}}, "embedding": [-0.10849584639072418, -0.18144065141677856, 0.011642699129879475, -0.05467384308576584, 0.09305033087730408, -0.0023291194811463356, -0.01844979263842106, 0.10642479360103607, 0.02421724982559681, 0.10279922187328339, -0.04084507003426552, 0.2009403556585312, -0.033578723669052124, 0.017391042783856392, -0.03632009029388428, 0.025292636826634407, -0.0170704647898674, -0.00018070638179779053, -0.13628898561000824, 0.034289974719285965, 0.10919369757175446, 0.13733384013175964, -0.020865632221102715, 0.05663714185357094, -0.10787543654441833, -0.04257024824619293, -0.08350759744644165, -0.0018456142861396074, -0.16993066668510437, -0.08984121680259705, 0.046484511345624924, 0.03334485739469528, -0.007911352440714836, -0.03296121209859848, -0.03925662860274315, -0.007636607624590397, -0.15375494956970215, 0.055424824357032776, 0.0014638998545706272, -0.013259435072541237, 0.06084750220179558, -0.08654026687145233, -0.126518115401268, -0.04902329295873642, 0.07130853831768036, -0.10476815700531006, -0.0934932604432106, 0.029879756271839142, 0.051040999591350555, 0.15024307370185852, -0.17920935153961182, -0.08608224242925644, 0.02311030775308609, -0.015376880764961243, 0.02327893301844597, 0.0022511743009090424, -0.004579430446028709, -0.08615042269229889, 0.009151835925877094, 0.026756256818771362, 0.0775875449180603, -0.027790963649749756, -0.014502213336527348, 0.03429645299911499, 0.1315334141254425, 0.07812494039535522, 0.10928899049758911, 0.15717895328998566, 0.06544496864080429, 0.017273634672164917, 0.12053702771663666, -0.026335060596466064, -0.12121749669313431, 0.11540690064430237, 0.046297576278448105, 0.058497071266174316, 0.05366525799036026, 0.10948488861322403, 0.19458135962486267, -0.0045828260481357574, -0.007096597459167242, 0.03353416547179222, 0.06967101991176605, -0.01821310818195343, -0.03697294741868973, 0.10020117461681366, 0.07278929650783539, 0.05449383705854416, 0.023058142513036728, 0.029013238847255707, 0.004321229178458452, 0.010321954265236855, 0.09928521513938904, 0.06060720235109329, 0.04479314386844635, -0.08225004374980927, 0.01819835975766182, -0.16752281785011292, 0.019739679992198944, 0.013088688254356384, -0.03279203176498413, -0.024059385061264038, -0.13641862571239471, -0.20328393578529358, -0.01696692407131195, -0.02872879058122635, -0.039177872240543365, 0.016750017181038857, 0.011874509043991566, 0.025855086743831635, -0.07418154180049896, 0.045462530106306076, 0.010547308251261711, -0.05999276414513588, 0.011861130595207214, 0.18353736400604248, -0.05403513461351395, 0.025958918035030365, 0.2554478049278259, -0.07695349305868149, 0.06057088449597359, 0.0748317763209343, -0.08243778347969055, -0.09319260716438293, -0.045986808836460114, -0.05203711986541748, -0.1375136822462082, 5.966357494132834e-33, 0.023248467594385147, -0.048981569707393646, -0.03605377674102783, 0.07316675782203674, 0.08564057946205139, -0.01225059013813734, -0.04166160523891449, -0.06333991885185242, -0.14591653645038605, 0.03828161209821701, -0.09717923402786255, -0.03535688295960426, -0.02095199003815651, 0.07568532228469849, -0.032368727028369904, -0.05803479254245758, -0.07366943359375, 0.15955525636672974, -0.01059049554169178, -0.03476138785481453, 0.008368357084691525, -0.06973110884428024, -0.07983149588108063, 0.0010150116868317127, -0.06252112984657288, 0.09806112945079803, -0.03338347375392914, -0.012400463223457336, 0.09463523328304291, 0.08539044857025146, -0.09631060063838959, 0.08560626208782196, 0.07936540246009827, -0.08658088743686676, 0.08215154707431793, -0.07485372573137283, -0.12982098758220673, -0.13007575273513794, 0.025332331657409668, 0.10633394122123718, -0.006369449198246002, 0.01803448610007763, -0.18484607338905334, -0.028313977643847466, 0.09313920140266418, -0.04332513362169266, -0.13756334781646729, 0.06208845227956772, -0.07635685801506042, -0.041435886174440384, 0.039887748658657074, 0.04054798558354378, 0.059794917702674866, -0.07852586358785629, 0.009572778828442097, -0.020735206082463264, -0.14403750002384186, -0.1361866146326065, 0.06512607634067535, 0.0742199644446373, 0.05130560323596001, 0.07750198245048523, 0.0020354818552732468, 0.12793362140655518, -0.09241577982902527, 0.07744945585727692, -0.0801142230629921, -0.1418878436088562, -0.03157460317015648, 0.07226033508777618, -0.008434249088168144, -0.015691401436924934, 0.16690108180046082, -0.037964705377817154, 0.014529706910252571, -0.09740840643644333, -0.015331589616835117, 0.12034067511558533, 0.027429044246673584, 0.11578784137964249, -0.015801288187503815, 0.007331907283514738, -0.05285445228219032, 0.06183706223964691, 0.031021451577544212, -0.07774820178747177, 0.04807240515947342, -0.0442311093211174, -0.08697974681854248, 0.02107507921755314, 0.08474555611610413, -0.0681474432349205, -0.10458199679851532, 0.10790321230888367, 0.060636259615421295, -6.759863200711911e-33, -0.057618215680122375, -0.031524915248155594, -0.017315201461315155, -0.06419137120246887, -0.16003179550170898, 0.051009081304073334, 0.07050430774688721, -0.08930797874927521, 0.14177504181861877, -0.08787962794303894, 0.0017180107533931732, 0.005091228522360325, -0.14114677906036377, -0.09631270170211792, -0.025508133694529533, -0.0854082703590393, 0.10148628056049347, -0.05551654472947121, -0.1416972279548645, 0.025506161153316498, 0.14281639456748962, 0.027470849454402924, -0.10358643531799316, 0.07468686997890472, 0.03415481746196747, -0.02711521089076996, 0.07064451277256012, 0.17077308893203735, 0.07639989256858826, -0.0334068201482296, 0.03487759828567505, 0.026255952194333076, -0.2575450539588928, 0.05100240930914879, -0.01635773852467537, 0.02050306461751461, 0.17172770202159882, -0.1048191487789154, 0.06666446477174759, -0.1476629376411438, 0.07995434105396271, 0.03065663017332554, -0.07260759174823761, 0.07323085516691208, 0.04698178544640541, -0.006870563142001629, -0.024340897798538208, 0.021652143448591232, 0.11303368210792542, -0.04859020560979843, 0.06824152171611786, -0.029048817232251167, 0.1445525884628296, 0.038349226117134094, -0.07488510012626648, -0.016574202105402946, 0.11856012046337128, -0.03179667145013809, 0.006466893944889307, 0.042129456996917725, -0.023652877658605576, -9.054876863956451e-05, -0.012567847967147827, 0.020717043429613113, 0.03873709216713905, 0.06036850064992905, 0.07813504338264465, -0.04069444537162781, 0.08744636178016663, -0.09293395280838013, 0.02812746725976467, -0.07868808507919312, 0.1495061218738556, -0.06651963293552399, 0.04170510545372963, 0.05364973470568657, -0.0365520641207695, -0.043798916041851044, -0.15690672397613525, 0.05209408700466156, 0.043581586331129074, -0.0036109955981373787, -0.00836407020688057, -0.03068625181913376, 0.12210452556610107, 0.027638915926218033, 0.04183243587613106, 0.08394721150398254, -0.0415775440633297, 0.020879656076431274, -0.09763217717409134, -0.13606002926826477, -0.17543865740299225, 0.07436170428991318, 0.010135900229215622, -9.974334602702584e-08, 0.11501394212245941, 0.029125822708010674, -0.04516484588384628, -0.09115207195281982, -0.022944418713450432, 0.01653159037232399, -0.0006193555891513824, 0.02178731933236122, 0.03475964069366455, 0.012362243607640266, 0.1014757752418518, 0.19281482696533203, -0.10649829357862473, 0.013253752142190933, 0.01476017851382494, 0.0415831133723259, -0.1551198959350586, -0.04859612509608269, -0.08650101721286774, -0.15926097333431244, -0.1149689257144928, 0.05444926396012306, -0.02074486017227173, -0.021537043154239655, -0.0474294051527977, -0.10142934322357178, 0.16476252675056458, 0.09562742710113525, 0.021403495222330093, -0.0757613405585289, -0.03490639850497246, -0.006774883717298508, 0.031714800745248795, 0.03813976049423218, -0.09837277233600616, -0.06567372381687164, 0.0878712609410286, 0.06959570944309235, 0.0594930425286293, 0.14027930796146393, -0.044049374759197235, 0.024007871747016907, -0.003137914463877678, -0.006547875702381134, 0.04834746569395065, -0.03877214342355728, -0.02581719309091568, 0.0343908928334713, 0.07897084951400757, -0.07062060385942459, -0.029138652607798576, 0.07561161369085312, 0.0046992916613817215, -0.024609196931123734, -0.10637208819389343, 0.15837907791137695, -0.04076768085360527, -0.1488182544708252, 0.01875506527721882, 0.017799867317080498, 0.014164581894874573, -0.10047249495983124, 0.1334589123725891, 0.09500063210725784], "changes": {"1wk": 1.2176645845502239}}, {"text": "PREMIUM Sector Update: Tech Stocks Flat to Lower Premarket Thursday MT Newswires Thu, Jan 23, 2025, 5:12 PM 1 min read In This Article: GWRE +0.67% Technology stocks were flat to lower premarket Thursday with the SPDR S&P Semiconductor ETF (XSD) in PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-23T14:12:58+00:00", "sentiment": {"score": 0.028234651312232018, "confidence": 0.053141746670007706, "probabilities": {"positive": 0.053141746670007706, "negative": 0.024907095357775688, "neutral": 0.921951174736023}}, "embedding": [-0.181197851896286, -0.07839737087488174, 0.12469038367271423, 0.08114373683929443, 0.17457574605941772, -0.16712228953838348, -0.06703869253396988, 0.09617651253938675, -0.06670334190130234, -0.015241377055644989, 0.1385871320962906, 0.17151883244514465, -0.03739865869283676, 0.060649026185274124, 0.22489726543426514, 0.05190456658601761, 0.04097924008965492, -0.1417553424835205, 0.045065563172101974, 0.009592395275831223, -0.2041221410036087, -0.11387426406145096, -0.008446884341537952, -0.09090200066566467, 0.21944773197174072, -0.06578250974416733, 0.08325975388288498, -0.028858685865998268, -0.0029493668116629124, 0.0010730947833508253, -0.1204935684800148, 0.01901748590171337, 0.06555011123418808, 0.000778496265411377, -0.001714629353955388, -0.025213701650500298, 0.006284885574132204, -0.016308102756738663, 0.05593579262495041, 0.00835230853408575, 0.10560353845357895, -0.2440744936466217, -0.09941761195659637, 0.025793204084038734, -0.04830153286457062, -0.015066348016262054, 0.007067038677632809, -0.15065248310565948, 0.0371289886534214, -0.11728009581565857, 0.2220131754875183, -0.10036533325910568, -0.014394060708582401, -0.07832778245210648, -0.0944213718175888, 0.04881485924124718, -0.10628920048475266, -0.07499217987060547, 0.027865225449204445, -0.0811673253774643, -0.03276779502630234, -0.14129234850406647, 0.017695389688014984, 0.07536587119102478, -0.046156760305166245, 0.15709900856018066, 0.11063306033611298, 0.13736064732074738, -0.08924232423305511, -0.15022452175617218, 0.07034070789813995, 0.11271391063928604, -0.01701951026916504, -0.005779142491519451, 0.023563962429761887, 0.09026116877794266, 0.20064233243465424, 0.07690436393022537, 0.13899828493595123, -0.11722325533628464, -0.03012516163289547, 0.042320575565099716, 0.05112762749195099, -0.014238854870200157, -0.20873026549816132, -0.03453768417239189, -0.03003351204097271, -0.1162465512752533, -0.09883641451597214, -0.177035391330719, 0.22073592245578766, 0.0263056717813015, -0.11193088442087173, 0.09738519042730331, -0.09287621080875397, -0.017851611599326134, -0.08464828133583069, -0.2283514440059662, -0.16856835782527924, 0.0765681341290474, 0.11416861414909363, 0.11653930693864822, -0.038218747824430466, 0.09414215385913849, -0.16360145807266235, -0.15726323425769806, -0.09807201474905014, 0.213994100689888, -0.0629173144698143, 0.07429473102092743, 0.07223203033208847, 0.1514710783958435, 0.03492868319153786, -0.13783930242061615, -0.22382493317127228, 0.06997731328010559, -0.19368870556354523, 0.08497253060340881, 0.004681500140577555, -0.0719473585486412, -0.02564975433051586, 0.07101961225271225, -0.13694392144680023, 0.05034145712852478, 0.031703881919384, 0.014781438745558262, 0.03371988236904144, 1.298503663290498e-32, 0.009522225707769394, 0.20527896285057068, -0.05974123254418373, -0.20172126591205597, -0.0793246477842331, -0.03906331583857536, 0.10721921175718307, -0.06426134705543518, -0.048421867191791534, 0.03724873438477516, -0.11310945451259613, 0.134893536567688, -0.19857913255691528, -0.08365058153867722, -0.030034730210900307, -0.29015642404556274, -0.04048248380422592, 0.11424627900123596, 0.1734650433063507, -0.0252908393740654, -0.013818100094795227, 0.002484284806996584, 0.014586604200303555, -0.211065873503685, 0.00788975041359663, 0.045686908066272736, 0.059526797384023666, -0.097129687666893, -0.04093504697084427, 0.10971961915493011, -0.12526407837867737, 0.07828817516565323, 0.07906033098697662, -0.011800368316471577, -0.003704353468492627, 0.14124338328838348, -0.13774915039539337, -0.12897160649299622, -0.00270757544785738, -0.13185809552669525, -0.03094939887523651, 0.04449877887964249, -0.17156793177127838, -0.17748700082302094, 0.07598146051168442, 0.04167552664875984, 0.06670807301998138, -0.1325726956129074, 0.023053424432873726, -0.019935371354222298, -0.10240620374679565, 0.15189231932163239, -0.19756099581718445, 0.14095591008663177, 0.004493136424571276, 0.05144061520695686, 0.060001764446496964, -0.21793480217456818, 0.06951696425676346, 0.03322162851691246, 0.14430978894233704, 0.13851642608642578, -0.05471504479646683, -0.11874832212924957, -0.23030683398246765, 0.10298007726669312, 0.058052558451890945, -0.0034463086631149054, -0.12377762049436569, 0.18096604943275452, 0.14363440871238708, -0.1337910294532776, 0.05062197893857956, 0.00871555507183075, -0.002589981537312269, 0.09881588816642761, -0.08006860315799713, 0.08597172796726227, 0.17131072282791138, 0.037254031747579575, 0.054200608283281326, 0.025906726717948914, 0.06713814288377762, 0.01046321913599968, 0.08721495419740677, 0.0475032664835453, 0.05431187525391579, 0.03157144412398338, 0.01510598137974739, 0.05210806429386139, -0.05940830335021019, -0.10970824211835861, -0.055823490023612976, 0.12119606137275696, 0.034380581229925156, -1.326193461281674e-32, -0.02052772231400013, 0.036327868700027466, -0.07873961329460144, -0.03769369423389435, -0.06718681007623672, -0.14949262142181396, 0.10882215946912766, 0.13703233003616333, 0.03828106448054314, 0.20751239359378815, 0.08819518983364105, 0.15567661821842194, -0.1827012300491333, -0.05775737762451172, 0.08260297030210495, -0.0312783308327198, 0.03871024027466774, -0.10084441304206848, 0.027591992169618607, 0.12582534551620483, 0.04577574506402016, -0.009116299450397491, -0.15997016429901123, 0.19751282036304474, 0.202579066157341, -0.021726325154304504, 0.019751176238059998, 0.26258546113967896, -0.03080233745276928, -0.04798213019967079, -0.006630368996411562, -0.09124938398599625, 0.015995671972632408, 0.01687270775437355, 0.0877242386341095, -0.110531747341156, 0.1157173365354538, 0.15252353250980377, -0.024512464180588722, -0.15808750689029694, 0.031049218028783798, -0.0490412563085556, 0.031406570225954056, 0.08476065844297409, 0.030097197741270065, 0.05848265439271927, -0.03460288047790527, -0.07399264723062515, 0.12856228649616241, -0.029158728197216988, -0.08346579968929291, 0.12305786460638046, 0.17667999863624573, 0.08766323328018188, -0.14706502854824066, 0.005256125703454018, 0.015367496758699417, 0.07386594265699387, -0.14922642707824707, -0.0703771710395813, 0.03533923253417015, 0.08818279951810837, 0.028665991500020027, -0.03461098298430443, 0.022819582372903824, -0.09325774013996124, 0.17780953645706177, -0.12918995320796967, -0.05938025191426277, -0.08839873969554901, -0.04438580572605133, -0.02925162948668003, -0.07857105880975723, -0.2979300916194916, 0.030192838981747627, 0.1350737065076828, 0.03146504983305931, 0.04446167126297951, 0.021612219512462616, 0.019012758508324623, 0.0217788964509964, 0.04341592639684677, 0.01559026725590229, 0.00658201752230525, -0.11511342227458954, 0.046983059495687485, 0.11338100582361221, -0.07191173732280731, -0.004119691904634237, 0.02354215830564499, -0.22282539308071136, -0.06937500834465027, 0.013121829368174076, 0.1155402883887291, -0.0667305514216423, -9.987036975189767e-08, -0.04877327010035515, -0.16006380319595337, 0.02027973160147667, -0.006840219721198082, 0.0887482538819313, -0.09521373361349106, 0.021037878468632698, 0.02438289299607277, -0.04824230447411537, 0.09932376444339752, -0.050439152866601944, -0.058103665709495544, -0.14331893622875214, -0.08107683062553406, 0.04097870737314224, -0.052603691816329956, -0.10542891919612885, 0.13358661532402039, -0.029327014461159706, -0.20276030898094177, 0.1351320892572403, 0.09109494835138321, 0.2610609531402588, -0.07451092451810837, 0.10677329450845718, 0.08027198910713196, 0.08171112835407257, -0.03682153671979904, 0.12138057500123978, 0.04759964346885681, -0.07763718068599701, -0.047759342938661575, -0.01380459126085043, 0.09110686928033829, 0.16597479581832886, 0.08983863145112991, 0.18872132897377014, 0.0967770516872406, 0.10052815079689026, 0.07607447355985641, -0.10085862129926682, -0.09230133146047592, 0.0773271769285202, 0.025682931765913963, 0.003612126922234893, 0.03811458870768547, -0.13531066477298737, -0.037569280713796616, 0.20631080865859985, -0.10374555736780167, 0.040260303765535355, -0.17566320300102234, -0.05654586851596832, -0.005276080686599016, -0.06829249858856201, 0.03349261358380318, -0.04211398586630821, -0.004936861805617809, -0.2919656038284302, 0.14035600423812866, 0.09331248700618744, -0.3416407108306885, 0.044403981417417526, 0.08634506911039352], "changes": {"1wk": -7.338596717677241}}, {"text": "PREMIUM Sector Update: Health Care Stocks Rise Premarket Tuesday MT Newswires Tue, Jan 21, 2025, 5:11 PM 1 min read In This Article: ARWR -5.73% NANO.PA +0.06% Health care stocks rose premarket Tuesday with the iShares Biotechnology ETF (IBB) 0.6% higher and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-21T14:11:51+00:00", "sentiment": {"score": 0.15542763005942106, "confidence": 0.16644974052906036, "probabilities": {"positive": 0.16644974052906036, "negative": 0.011022110469639301, "neutral": 0.8225281834602356}}, "embedding": [-0.11563417315483093, -0.15356914699077606, -0.01624089665710926, 0.13806875050067902, 0.17985710501670837, -0.021896105259656906, -0.03183135390281677, 0.005216752644628286, 0.013951010070741177, 0.06588396430015564, 0.049899689853191376, 0.14053496718406677, -0.08599244058132172, -0.031484607607126236, 0.052388958632946014, -0.039615198969841, 0.0325738787651062, -0.13137614727020264, -0.01790124550461769, 0.06131625175476074, -0.2074626088142395, -0.01901199109852314, 0.061245474964380264, 0.011858353391289711, 0.1598837971687317, -0.04897318780422211, -0.017333051189780235, -0.04403520002961159, -0.02438323013484478, -0.0529739074409008, 0.03656550869345665, -0.0328497551381588, 0.15291878581047058, -0.048216916620731354, -0.046612776815891266, -0.03365378826856613, 0.05645204335451126, 0.02674407884478569, -0.05915665999054909, 0.0008758046315051615, 0.0966203361749649, -0.20417757332324982, -0.12451129406690598, 0.09807492047548294, 0.09884770214557648, 0.03358565270900726, -0.04787135869264603, 0.014495257288217545, 0.09611454606056213, -0.00977118220180273, -0.04336310178041458, -0.14175909757614136, 0.04497719556093216, 0.02480187825858593, -0.011644040234386921, -0.05213065445423126, -0.13370420038700104, -0.17933644354343414, -0.045117203146219254, -0.02460436150431633, -0.08895639330148697, -0.039130426943302155, 0.053866516798734665, 0.09915345907211304, -0.07904404401779175, 0.13703735172748566, 0.07894075661897659, 0.23467248678207397, 0.019717253744602203, -0.10696770250797272, 0.007502436637878418, -0.036177702248096466, 0.056637514382600784, 0.13031059503555298, 0.049544189125299454, 0.09569384902715683, 0.12176409363746643, -0.004535024520009756, 0.19692686200141907, -0.12572960555553436, 0.003961397800594568, -0.01269347220659256, 0.08303766697645187, 0.06514961272478104, -0.062038104981184006, -0.018708402290940285, -0.024251777678728104, -0.14872148633003235, -0.08029916882514954, -0.1904754936695099, 0.20566698908805847, -0.011030194349586964, -0.03368999809026718, 0.05938210338354111, -0.0030780949164181948, -0.01997276395559311, -0.16917556524276733, -0.18158210813999176, -0.14272335171699524, -0.0045121521688997746, 0.05179676413536072, 0.013000267557799816, -0.08889946341514587, 0.1747090071439743, -0.07426389306783676, -0.2356525957584381, -0.05142367631196976, 0.1138044074177742, 0.15058298408985138, 0.18573443591594696, 0.06677405536174774, 0.1308264583349228, 0.03329095616936684, -0.11801652610301971, -0.13654543459415436, 0.13035792112350464, -0.05313979461789131, -0.04382700100541115, 0.10060396790504456, 0.04574939236044884, -0.004734738264232874, 0.15685488283634186, -0.17349547147750854, 0.008882272988557816, 0.0015011581126600504, 0.07055811583995819, -0.019184047356247902, 1.2213653730008379e-32, -0.027889614924788475, 0.1211848333477974, 0.11566641926765442, -0.07046966254711151, -0.09213148802518845, -0.05026363953948021, 0.07677645981311798, -0.19022908806800842, -0.06725415587425232, -0.0862390398979187, -0.19034716486930847, 0.1384013593196869, -0.009853659197688103, 0.013767627999186516, -0.13323968648910522, -0.2563149929046631, -0.1218794733285904, 0.10158968716859818, 0.07284106314182281, 0.11943624913692474, -0.09825406968593597, -0.05349041521549225, -0.07615137100219727, -0.038048356771469116, -0.043619297444820404, 0.06808674335479736, 0.09379062801599503, -0.1147603690624237, 0.08781545609235764, 0.12713946402072906, -0.08101549744606018, 0.12042435258626938, -0.07588392496109009, -0.14355270564556122, -0.06462457776069641, 0.04732397571206093, -0.030164193361997604, 0.0075200702995061874, -0.02653912454843521, -0.08636166900396347, -0.0471639558672905, -0.01041565090417862, -0.12209419161081314, -0.06779266893863678, 0.03385811299085617, 0.03633402660489082, -0.03810301050543785, -0.05061888322234154, 0.09122499078512192, -0.07171585410833359, -0.1451399028301239, 0.05758027359843254, -0.1398974359035492, 0.009322110563516617, 0.03273317590355873, 0.055250320583581924, -0.01512584276497364, -0.060300298035144806, 0.05181937292218208, 0.018198849633336067, 0.11800461262464523, 0.10389818251132965, -0.023665137588977814, 0.01803097501397133, -0.25323787331581116, 0.10538715124130249, -0.09012659639120102, -0.020566632971167564, -0.04225996881723404, 0.24754242599010468, 0.1385120451450348, -0.023623008280992508, -0.016482040286064148, -0.02758168801665306, -0.12369406223297119, 0.085739366710186, -0.12628701329231262, 0.08382107317447662, 0.12321297824382782, 0.08836115896701813, 0.04716963320970535, -0.021367335692048073, 0.08017510920763016, 0.07147566974163055, 0.1422056406736374, 0.010753202252089977, 0.016106855124235153, 0.07346809655427933, 0.012753233313560486, -0.07396849989891052, 0.02956325374543667, 0.02987186424434185, 0.0855291411280632, 0.10008975863456726, -0.03415682539343834, -1.4150614219510144e-32, 0.06476148217916489, 0.06280159950256348, -0.08599833399057388, -0.07303369790315628, -0.0906980112195015, -0.025375904515385628, 0.036745376884937286, 0.1474607288837433, 0.13606604933738708, 0.1513303965330124, 0.1101614311337471, 0.0983959510922432, -0.17026387155056, 0.027771275490522385, 0.06912288069725037, -0.03856923431158066, 0.0003784994187299162, -0.1857929527759552, -0.009454688988626003, 0.10498286783695221, -0.08640865981578827, 0.01686076819896698, -0.13034234941005707, 0.2475387454032898, 0.06385866552591324, 0.05526639521121979, 0.010782316327095032, 0.2049226015806198, 0.08370408415794373, -0.20510448515415192, -0.16544723510742188, -0.04842172935605049, -0.10524267703294754, 0.045920100063085556, -0.04868176579475403, -0.057611119002103806, 0.14216095209121704, -0.003482252825051546, -0.08663028478622437, -0.10927557200193405, 0.09189362078905106, -0.11553513258695602, -0.09405960887670517, 0.007010369561612606, 0.03897840157151222, 0.05364729464054108, -0.03978976979851723, 0.11194481700658798, 0.126991406083107, -0.06150534003973007, -0.05376347526907921, 0.04582977294921875, 0.08152680099010468, 0.16023403406143188, -0.2183324694633484, -0.03916219621896744, 0.027403082698583603, 0.019370945170521736, -0.15381714701652527, -0.05572093650698662, 0.05977882817387581, 0.13944509625434875, -0.12835650146007538, -0.10771109163761139, -0.05455752834677696, -0.007482488173991442, 0.12176896631717682, -0.12572018802165985, 0.032900482416152954, -0.11921950429677963, -0.02776188962161541, -0.05103125795722008, -0.08558210730552673, -0.2884787917137146, 0.05867289379239082, 0.11450135707855225, 0.05536922439932823, 0.03739788383245468, -0.08207788318395615, 0.0834161639213562, 0.07824310660362244, -0.03720840439200401, -0.03863542899489403, 0.0208094771951437, -0.17086774110794067, 0.06373229622840881, 0.06911364197731018, -0.13044975697994232, -0.05834483727812767, 0.09681135416030884, -0.24272428452968597, -0.07418031245470047, -0.18480758368968964, 0.08950553834438324, -0.010349053889513016, -1.0029857122617614e-07, 0.06489080935716629, -0.10297597199678421, 0.07743418961763382, -0.024534661322832108, 0.0575547069311142, -0.1133425161242485, -0.08017946034669876, 0.10514650493860245, 0.07306233793497086, 0.16774362325668335, -0.0025423727929592133, 0.14787733554840088, -0.015253549441695213, -0.06439491361379623, 0.021182896569371223, -0.08932517468929291, -0.1717659831047058, 0.07984872162342072, -0.0033765826374292374, -0.16624638438224792, 0.02592136710882187, 0.10023528337478638, 0.18339623510837555, -0.1278543919324875, 0.019962821155786514, 0.07047811150550842, -0.012856976129114628, -0.1335832178592682, 0.06709928810596466, 0.018851079046726227, -0.07799141108989716, -0.006190427578985691, -0.033244505524635315, 0.03669152408838272, 0.015520092099905014, 0.035510092973709106, 0.13445140421390533, -0.057588547468185425, 0.06955554336309433, 0.05248786509037018, 0.030693702399730682, -0.06443513184785843, 0.009064579382538795, -0.001785606611520052, -0.04453255981206894, -0.0022320481948554516, -0.06468834728002548, 0.030493399128317833, 0.19722598791122437, -0.18028569221496582, -0.02621947042644024, -0.08550526946783066, 0.10536688566207886, -0.01632123999297619, -0.11467403918504715, 0.13332250714302063, -0.07233155518770218, -0.1625964194536209, -0.13592858612537384, 0.2110278457403183, 0.21259789168834686, -0.36807358264923096, 0.10081981122493744, 0.16071529686450958], "changes": {"1wk": 2.479755897988124}}, {"text": "PREMIUM Arrowhead Pharmaceuticals' New Drug Application for Plozasiran Accepted by FDA MT Newswires Sat, Jan 18, 2025, 1:02 AM 1 min read In This Article: ARWR -5.73% Arrowhead Pharmaceuticals (ARWR) said late Friday that its new drug application for plozasiran to tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-17T22:02:02+00:00", "sentiment": {"score": 0.04638941679149866, "confidence": 0.05945459008216858, "probabilities": {"positive": 0.05945459008216858, "negative": 0.013065173290669918, "neutral": 0.9274802207946777}}, "embedding": [-0.12249638885259628, -0.2565232217311859, -0.08375567197799683, -0.1675311177968979, 0.05936998501420021, -0.05033053085207939, 0.10273470729589462, 0.2308729588985443, -0.07780241221189499, 0.008130397647619247, -0.018392648547887802, 0.23379260301589966, -0.009176979772746563, 0.10899551957845688, 0.05158490315079689, 0.08128885924816132, 0.06411570310592651, -0.08366118371486664, 0.1480737179517746, 0.00230616913177073, -0.05728878080844879, 0.002716892398893833, 0.06916870176792145, 0.04268183931708336, -0.1428724229335785, 0.12170646339654922, -0.08016680926084518, 0.12581732869148254, 0.03350380063056946, -0.07431802153587341, 0.05529650300741196, -0.004272241611033678, 0.11064376682043076, -0.12203779816627502, -0.08466150611639023, -0.04123798757791519, -0.1477910429239273, 0.09507784247398376, -0.2415698766708374, -0.026712927967309952, 0.07066604495048523, -0.08965642005205154, -0.1968313306570053, 0.12996293604373932, 0.08758987486362457, -0.279766708612442, -0.05408117547631264, 0.18441130220890045, 0.07317151874303818, 0.23550699651241302, 0.05515342578291893, -0.23802423477172852, 0.034326497465372086, -0.026235029101371765, 0.07245967537164688, -0.020066101104021072, -0.2690642476081848, -0.11210238188505173, 0.005243034102022648, -0.09776806831359863, -0.08486112207174301, 0.05198297277092934, -0.17350129783153534, 0.043291036039590836, -0.03443639725446701, 0.14562766253948212, -0.03580661490559578, 0.12591031193733215, 0.05188605189323425, -0.02206994965672493, 0.02709626592695713, -0.02774854749441147, 0.023819269612431526, 0.015274286270141602, -0.01174731645733118, 0.04317246377468109, 0.12076203525066376, -0.021309413015842438, 0.060320861637592316, -0.05100640282034874, -0.003257867880165577, 0.03405991569161415, -0.006942171137779951, 0.046333346515893936, 0.03125428780913353, 0.11034537106752396, -0.06044868379831314, -0.06203753501176834, -0.004135360941290855, -0.10880200564861298, 0.2983274757862091, -0.010472520254552364, 0.006970283109694719, -0.05021196976304054, -0.06299412250518799, 0.07591764628887177, -0.1632630079984665, -0.08974618464708328, -0.20142750442028046, 0.09483717381954193, 0.03132002428174019, -0.16367283463478088, -0.1563330739736557, -0.1363184154033661, -0.09758830815553665, -0.07730184495449066, 0.10355706512928009, 0.11757531017065048, 0.0206304918974638, 0.08546330034732819, -0.07202346622943878, 0.016088007017970085, 0.10226675868034363, 0.0016442339401692152, -0.09924259781837463, 0.16005770862102509, -0.11654588580131531, -0.03149886056780815, 0.1277572065591812, -0.006775456480681896, -0.03589308261871338, 0.1532745063304901, -0.01197412796318531, -0.06367312371730804, 0.0020445247646421194, -0.016934985294938087, -0.06488475203514099, 1.093995637706649e-32, -0.0971728041768074, 0.08289589732885361, 0.11133448779582977, -0.09863267838954926, 0.051859255880117416, 0.010885742492973804, 0.009266586974263191, -0.09510134905576706, -0.20578321814537048, -0.09249752759933472, -0.13246510922908783, 0.05826772376894951, -0.14643512666225433, 0.20122161507606506, -0.04389437660574913, -0.14464151859283447, -0.0433083139359951, 0.19597168266773224, 0.2160448133945465, 0.04101883992552757, 0.008831546641886234, -0.06450659036636353, -0.09256433695554733, 0.04843387007713318, -0.13038913905620575, 0.25603941082954407, 0.07357504218816757, 0.059809282422065735, 0.16991834342479706, 0.12543857097625732, -0.13711956143379211, 0.19346685707569122, -0.0339951254427433, -0.12665298581123352, -0.022950969636440277, -0.026583576574921608, -0.04019993171095848, -0.09403019398450851, -0.06027965992689133, -0.055706556886434555, 0.11772971600294113, -0.08448837697505951, -0.26924189925193787, 0.0953783467411995, 0.10165579617023468, -0.06018570810556412, -0.0941835343837738, 0.05576719343662262, -0.020844634622335434, -0.00472596287727356, 0.018892208114266396, 0.0285823792219162, -0.06421133130788803, 0.04649263992905617, -0.1822529137134552, 0.04161696881055832, -0.26649388670921326, -0.010718604549765587, 0.2413381040096283, -0.11819087713956833, 0.14198771119117737, 0.07121474295854568, 0.044472549110651016, -0.0025339347776025534, -0.19562071561813354, -0.053879547864198685, -0.15191835165023804, -0.15725179016590118, -0.005397974979132414, 0.16650345921516418, 0.0531146414577961, 0.0429130420088768, -0.08991795778274536, 0.06464052945375443, 0.16989052295684814, -0.08101917058229446, -0.002214645268395543, 0.19129811227321625, 0.2195156216621399, 0.04201987385749817, -0.03090851940214634, -0.08593502640724182, -0.02634405344724655, 0.11099841445684433, -0.010761657729744911, -0.016182417050004005, 0.05638161301612854, -0.0927651971578598, -0.09306440502405167, 0.09094041585922241, 0.12017649412155151, 0.017577212303876877, -0.15197382867336273, 0.13026444613933563, 0.029494861140847206, -1.2968297593349271e-32, -0.06525837630033493, -0.07756919413805008, 0.10418607294559479, -0.012353690341114998, -0.10856689512729645, 0.041296374052762985, -0.05126086622476578, 0.09261143952608109, 0.26846548914909363, 0.05639901012182236, 0.03371845558285713, 0.09643565863370895, -0.1089845597743988, -0.04335258901119232, 0.11841613054275513, 0.05865577980875969, 0.0478508435189724, -0.13287055492401123, -0.09327848255634308, 0.024181857705116272, -0.0434759296476841, -0.03834788501262665, -0.11151573807001114, 0.07579274475574493, 0.06126084178686142, -0.041935112327337265, 0.18942654132843018, 0.2309568077325821, 0.018785789608955383, -0.05743065103888512, -0.026685401797294617, 0.008595035411417484, -0.29381051659584045, -0.04389943927526474, -0.15612290799617767, -0.06824842095375061, 0.23146428167819977, 0.06696456670761108, -0.07327183336019516, -0.10517317801713943, 0.09630563855171204, -0.05438905581831932, -0.11649151146411896, 0.10541372001171112, 0.12510906159877777, 0.1411687135696411, 0.0456167571246624, -0.05912152677774429, 0.11382292211055756, -0.15649907290935516, 0.07849715650081635, -0.007080489303916693, 0.21382570266723633, 0.016169605776667595, 0.032944586127996445, -0.05177149921655655, 0.06764382123947144, -0.02431575581431389, 0.05726996064186096, -0.01474243588745594, -0.017003679648041725, -0.024977289140224457, -0.23940595984458923, -0.023140106350183487, 0.175694078207016, -0.05573832988739014, 0.18771091103553772, -0.09210998564958572, -0.015467150136828423, -0.08253545314073563, -0.09950510412454605, -0.15902215242385864, 0.02401900850236416, 0.003467395668849349, 0.03492066264152527, 0.15126933157444, 0.07442865520715714, -0.11586527526378632, -0.12155214697122574, -0.14056023955345154, -0.013497200794517994, -0.09006009250879288, -0.018373040482401848, -0.09643419831991196, -0.01256781816482544, -0.04817328229546547, 0.11809656769037247, 0.004271102137863636, -0.05258755758404732, 0.18827101588249207, -0.11599856615066528, -0.04618048295378685, -0.19808313250541687, 0.08063331991434097, 0.09825956076383591, -1.010184718097662e-07, 0.12795189023017883, -0.0689493790268898, -0.03574555367231369, -0.015393190085887909, -0.016796864569187164, 0.12916846573352814, -0.060347311198711395, -0.008655799552798271, 0.0472869873046875, 0.028950784355401993, -0.04806949198246002, 0.10368391871452332, -0.027729259803891182, 0.09540199488401413, 0.07360894232988358, 0.1033477783203125, 0.1149277612566948, 0.0011107238242402673, -0.0713648572564125, -0.16269777715206146, -0.21681615710258484, 0.21483533084392548, 0.1156218871474266, -0.013474064879119396, -0.028742196038365364, -0.1358405500650406, 0.06645409017801285, -0.027749521657824516, 0.05153120309114456, -0.03615964204072952, -0.055045343935489655, 0.07392207533121109, 0.0993410125374794, -0.01862517185509205, -0.036484356969594955, -0.016518138349056244, -0.012601212598383427, 0.06226969137787819, 0.1967274248600006, -0.05470278486609459, -0.0005785632529295981, -0.02360459417104721, 0.018839683383703232, -0.11008991301059723, -0.09270339459180832, -0.1221555843949318, -0.025321494787931442, -0.06624570488929749, 0.11306070536375046, -0.09410715103149414, 0.057217344641685486, 0.08482788503170013, 0.11638211458921432, -0.2403908669948578, 0.007997994311153889, 0.08563584089279175, -0.048195626586675644, -0.37336376309394836, -0.02682127058506012, -0.16157862544059753, 0.15735986828804016, -0.18812087178230286, 0.0496603287756443, 0.08248448371887207], "changes": {"1wk": 6.134973393168435}}, {"text": "Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome Business Wire Sat, Jan 18, 2025, 12:30 AM 6 min read In This Article: ARWR -5.73% - The New Drug Application is based on positive results from the Phase 3 PALISADE study - People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including poor quality of life PASADENA, Calif., January 17, 2025 --( BUSINESS WIRE )--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025. \"With the plozasiran NDA submission and FDA\u2019s acceptance for filing complete, we are laser focused on our ongoing work to ensure an efficient and successful commercial launch this year, pending FDA review and approval. We would like to thank all Arrowhead employees and the investigators, patients, and caregivers who contributed to the PALISADE Phase 3 study of plozasiran in patients with genetically confirmed or clinically diagnosed FCS,\" said Chris Anzalone, Ph.D., President and CEO at Arrowhead. \"Plozasiran has achieved promising and consistent results in various patient populations representing multiple points on the spectrum of diseases caused by elevated triglycerides. FCS represents the most severe and rare end of the spectrum; however, we believe that substantial unmet medical need exists in severe hypertriglyceridemia and mixed hyperlipidemia, which we are investigating in additional Phase 3 trials as part of the SUMMIT program of clinical studies.\" The clinical basis of the NDA submission is comprised of the positive findings in the Phase 3 PALISADE study with supportive confirmatory evidence from the Phase 2 clinical studies of the SUMMIT Program. PALISADE successfully met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipoprotein C-III (APOC3), and the incidence of acute pancreatitis (AP). In PALISADE, plozasiran achieved deep and durable reductions in triglycerides with a median change from baseline of 80% in the plozasiran 25 mg group and a statistically significant 83% reduction in the risk of developing acute pancreatitis compared to placebo in the pooled plozasiran 25 mg and 50 mg group. Overall, plozasiran has been generally well-tolerated to date. In the PALISADE study, the most frequently reported treatment emergent adverse events for the 25 mg dose that is proposed for marketing approval were abdominal pain, COVID-19, nasopharyngitis, and nausea. Story Continues The efficacy and safety results from the PALISADE study were presented at the American Heart Association Scientific Sessions 2024 (AHA24) and simultaneously published in Circulation and presented at the European Society of Cardiology (ESC) Congress 2024 and simultaneously published in The New England Journal of Medicine . AHA24, ESC, and other plozasiran presentations may be accessed on the Events and Presentations page in the Investors section of the Arrowhead website. About Familial Chylomicronemia Syndrome Familial chylomicronemia syndrome (FCS) is a severe and rare disease often caused by various monogenic mutations. FCS leads to extremely high triglyceride (TG) levels, typically over 880 mg/dL. Such severe elevations can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. Currently, there are limited therapeutic options to adequately treat FCS. About Plozasiran Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by hepatic receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels. In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose that is proposed for marketing approval were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain. Plozasiran is being investigated in the SUMMIT program of clinical studies, including the PALISADE Phase 3 study in patients with FCS, the SHASTA studies in patients with SHTG, and the MUIR and CAPITAN studies in patients with mixed hyperlipidemia. Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the European Medicines Agency. Investigational plozasiran has not been reviewed or approved to treat any disease. About PALISADE Phase 3 Study The PALISADE study ( NCT05089084 ) is a Phase 3 placebo controlled study to evaluate the efficacy and safety of plozasiran in adults with genetically confirmed or clinically diagnosed FCS. The primary endpoint of the study is percent change from baseline in fasting TG versus placebo at Month 10. A total of 75 subjects distributed across 39 different sites in 18 countries were randomized to receive 25 mg plozasiran, 50 mg plozasiran, or matching placebo once every three months. Participants who completed the randomized period were eligible to continue in a 2-part extension period, where all participants receive plozasiran. About Plozasiran EAP Arrowhead is committed to bringing new investigational medicines to patients with serious diseases as quickly and efficiently as possible. The company has established an expanded access program (EAP) for some individuals living with FCS. As with any investigational medicine that has not been approved by regulatory authorities, investigational plozasiran may or may not be effective in treating your diagnosis or condition, and there may be risks associated with its use. If you are a patient or caregiver wishing to know more about this plozasiran EAP for FCS, please discuss this EAP and all treatment options with your treating physician. If you are a treating physician and are seeking information about the plozasiran EAP or would like to request access for a patient, please contact EAP@arrowheadpharma.com . About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead\u2019s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com , or follow us on X (formerly Twitter) at @ArrowheadPharma , LinkedIn , Facebook , and Instagram . To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as \"may,\" \"will,\" \"expect,\" \"believe,\" \"anticipate,\" \"hope,\" \"intend,\" \"plan,\" \"project,\" \"could,\" \"estimate,\" \"continue,\" \"target,\" \"forecast\" or \"continue\" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20250117349461/en/ Contacts Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 ir@arrowheadpharma.com Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com Media: LifeSci Communications, LLC Kendy Guarinoni, Ph.D. 724-910-9389 kguarinoni@lifescicomms.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-17T21:30:00+00:00", "sentiment": {"score": 0.2745540402829647, "confidence": 0.2899995744228363, "probabilities": {"positive": 0.2899995744228363, "negative": 0.015445534139871597, "neutral": 0.6945549249649048}}, "embedding": [-0.08210647106170654, -0.18503126502037048, -0.1010904610157013, -0.10273092985153198, -0.07043042033910751, -0.025401443243026733, -0.022554440423846245, 0.25307726860046387, 0.024217689409852028, -0.062879778444767, -0.051268644630908966, 0.044088929891586304, -0.026396965608000755, 0.08645562082529068, -0.043851353228092194, 0.003884617704898119, -0.04051203280687332, -0.08103545010089874, -0.048285502940416336, 0.062327414751052856, 0.03517701476812363, 0.0013229679316282272, 0.0662865936756134, 0.0487205907702446, -0.16028714179992676, -0.027244996279478073, -0.0526270791888237, -0.028799477964639664, -0.06073048710823059, -0.024391284212470055, 0.06371570378541946, 0.19754986464977264, 0.047370053827762604, -0.05077508091926575, 0.02836013026535511, -0.02250225469470024, -0.0884779542684555, 0.03988098353147507, -0.08127985894680023, 0.0032458938658237457, 0.020071877166628838, -0.08105628192424774, -0.14266721904277802, 0.08655396103858948, 0.061119500547647476, -0.22307080030441284, -0.03233099728822708, 0.10047538578510284, -0.0016807150095701218, 0.22969487309455872, -0.10274385660886765, -0.15051409602165222, 0.057502247393131256, 0.040029581636190414, 0.02053225412964821, -0.04800846055150032, -0.07926161587238312, -0.0722292959690094, -0.024987192824482918, -0.04738939553499222, -0.059561967849731445, -0.016230836510658264, -0.06611011922359467, -0.04627824202179909, 0.05759847164154053, 0.08226129412651062, -0.007336821407079697, -0.11653553694486618, 0.1126471683382988, 0.004603425040841103, 0.08831359446048737, -0.04421408101916313, -0.09349449723958969, 0.09159587323665619, -0.0391995906829834, 0.1071171909570694, 0.09863857924938202, 0.07210683822631836, 0.10490085184574127, -0.10618523508310318, 0.04871752858161926, 0.051407232880592346, 0.043643414974212646, -0.06694789230823517, 0.024243319407105446, 0.05816671624779701, -0.06004204973578453, 0.11060620844364166, -0.10021805763244629, -0.033102232962846756, 0.14878106117248535, 0.004604620859026909, 0.05329255014657974, -0.06490013748407364, 0.008483976125717163, 0.009128931909799576, -0.011173918843269348, -0.15752282738685608, 0.01783553883433342, 0.0038952920585870743, 0.043343283236026764, -0.06253088265657425, -0.10524344444274902, -0.06847493350505829, -0.04412767291069031, 0.057020463049411774, 0.0596536248922348, -0.02025335468351841, -0.05079594999551773, -0.0017169853672385216, -0.08251549303531647, 0.02059038169682026, 0.11513657867908478, -0.015236537903547287, -0.09229031205177307, 0.17458489537239075, -0.09662957489490509, 0.04332127422094345, 0.20452743768692017, 0.05981559306383133, -0.009742869064211845, 0.036499787122011185, 0.012369636446237564, -0.0899142175912857, 0.07633741199970245, 0.019474992528557777, -0.08760262280702591, 1.244323953166748e-32, -0.0972328782081604, 0.07358822226524353, 0.02499258890748024, -0.03971448540687561, 0.002192877698689699, -0.02966957353055477, 0.09036296606063843, 0.02036471664905548, -0.09008955210447311, -0.03959028422832489, -0.07288791239261627, -0.011111410334706306, 0.0007645087316632271, 0.0828358456492424, -0.1474328190088272, -0.08639027923345566, -0.020725704729557037, 0.008815674111247063, -0.015153363347053528, 0.062335968017578125, 0.005145903676748276, -0.041373927146196365, 0.011815948411822319, -0.003566955216228962, -0.09598705172538757, 0.14575020968914032, 0.002578350715339184, 0.12403669953346252, 0.09365463256835938, 0.06261932849884033, -0.06217743456363678, 0.056822292506694794, 0.06314851343631744, -0.09354376047849655, -0.10949093103408813, -0.023343823850154877, 0.011514776386320591, -0.10372212529182434, -0.023518014699220657, 0.12305264174938202, -0.05792689323425293, 0.03251729905605316, -0.12910741567611694, 0.00585528276860714, 0.06312982738018036, -0.09353415668010712, -0.07918589562177658, 0.0001784072956070304, -0.09104931354522705, -0.02109161578118801, -0.029003232717514038, -0.022472703829407692, 0.08699838072061539, -0.002737884409725666, -0.006170367822051048, -0.013672598637640476, -0.16894492506980896, -0.06276676058769226, 0.10622261464595795, 0.011035604402422905, 0.1060328409075737, 0.13354529440402985, -0.06850385665893555, -0.011220271699130535, -0.1306447833776474, -0.028853248804807663, -0.05082561820745468, -0.08890755474567413, -0.05037303268909454, 0.01429530419409275, 0.030485305935144424, -0.049236640334129333, 0.1301446408033371, 0.03653942421078682, 0.1449754536151886, -0.10532579571008682, 0.07646776735782623, 0.10037411749362946, 0.055078886449337006, -0.040813639760017395, -0.04692920297384262, -0.009885113686323166, 0.034911371767520905, 0.0484398752450943, -0.016701165586709976, -0.05049733817577362, 0.024523336440324783, 0.022280454635620117, -0.1520143300294876, -0.03124176897108555, 0.0755903497338295, 0.03272796794772148, 0.017766708508133888, 0.18601006269454956, 0.06111733987927437, -1.1546773744267818e-32, -0.03304816037416458, -0.03236308693885803, -0.015982866287231445, -0.1259233057498932, -0.012872105464339256, 0.03421124815940857, 0.01470116339623928, -0.09665559232234955, 0.18846717476844788, -0.13788112998008728, -0.025955472141504288, 0.019597886130213737, -0.08112196624279022, -0.12714213132858276, -0.006162350997328758, 0.10670238733291626, -0.060176484286785126, -0.040479626506567, -0.08353562653064728, 0.057435132563114166, 0.018489161506295204, 0.1035960242152214, -0.21128256618976593, 0.10489345341920853, 0.028730254620313644, 0.06029488146305084, 0.11905749142169952, 0.07275869697332382, 0.023651445284485817, -0.03780747950077057, -0.03185746818780899, -0.04730596765875816, -0.21056509017944336, -0.003911757376044989, -0.022296132519841194, -0.13030129671096802, 0.09720274806022644, -0.03182530403137207, -0.043866753578186035, -0.018325578421354294, 0.05527973920106888, 0.11124706268310547, -0.0289810448884964, 0.08025593310594559, 0.06279957294464111, 0.01872956193983555, 0.017471803352236748, -0.07002761960029602, 0.13505998253822327, -0.06923092901706696, -0.02953759767115116, 0.005215167999267578, 0.08998672664165497, 0.07309971749782562, 0.02594512328505516, 0.015475333668291569, 0.10501477122306824, -0.06699138879776001, -0.028794974088668823, -0.02259122207760811, -0.01431584544479847, -0.05999112129211426, -0.07200732082128525, 0.08076627552509308, 0.23289501667022705, 0.030543282628059387, 0.08831355720758438, -0.047000735998153687, 0.09016631543636322, -0.020688891410827637, -0.15392065048217773, -0.07129903137683868, -0.037276383489370346, -0.002388215623795986, 0.03253350779414177, 0.05742146447300911, -0.06668896228075027, -0.09621777385473251, -0.048614293336868286, -0.056294336915016174, 0.0316464826464653, -0.11543086916208267, -0.014072584919631481, 0.014890674501657486, 0.0440443754196167, -0.0006433594971895218, 0.07298978418111801, 0.0122200483456254, 0.044990722090005875, 0.051029451191425323, -0.04994775354862213, -0.08558964729309082, -0.12694543600082397, 0.00844230130314827, 0.09025849401950836, -1.0107856240892943e-07, 0.16219587624073029, -0.09199613332748413, -0.08789602667093277, -0.03472200408577919, -0.024533264338970184, 0.00553881237283349, -0.09312554448843002, 0.03562740236520767, -0.0005285902880132198, 0.04917484149336815, -0.0029882173985242844, 0.20273205637931824, -0.09350647777318954, 0.005911753512918949, 0.020240694284439087, 0.03255772590637207, 0.04780179262161255, 0.10673747956752777, -0.05716278403997421, -0.03839021176099777, -0.14172285795211792, 0.11690354347229004, 0.018543165177106857, 0.02509441412985325, -0.004777250811457634, -0.04045305401086807, 0.16817624866962433, 0.10412725061178207, -0.012056393548846245, -0.028262261301279068, -0.07345655560493469, -0.01550399698317051, 0.037724096328020096, 0.07906217873096466, -0.01980261132121086, -0.10989342629909515, 0.04093095660209656, 0.15062545239925385, 0.0648958832025528, 0.08462144434452057, 0.026354506611824036, 0.04368150606751442, -0.052338942885398865, -0.02804604172706604, 0.02012920193374157, -0.14312395453453064, -0.08359340578317642, 0.025788789615035057, 0.05731318145990372, -0.10825647413730621, -0.04853532463312149, 0.04062856733798981, -0.006992746144533157, -0.0462309867143631, 0.00648256903514266, 0.16185970604419708, -0.10579617321491241, -0.08545632660388947, -0.07675789296627045, -0.060631245374679565, 0.13147017359733582, -0.002208729973062873, 0.1473233997821808, 0.0064234863966703415], "changes": {"1wk": 6.134973393168435}}, {"text": "SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? Sundeep Ganoria Mon, Jan 6, 2025, 3:40 PM 5 min read In This Article: SRPT +0.08% Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry\u2019s 15.7% decline, as shown in the chart below. During this timeframe, the stock has also outdone the broader Medical sector but slightly underperformed the S&P 500 Index. SRPT\u2019s shares are trading above the 50-day moving average. SRPT Stock Performance Zacks Investment Research Image Source: Zacks Investment Research The surge in the stock price can be attributed to the encouraging sales performance of Sarepta\u2019s Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Let\u2019s delve into the company\u2019s strengths and weaknesses to gain a better understanding of how to play the stock amid the price surge. Elevidys: A Key Contributor to Sarepta\u2019s Revenue Growth Currently, Elevidys is the first and only one-shot gene therapy for DMD in the United States. \u00a0A progressive and degenerative disorder, DMD leads to weakness and wasting away of the body\u2019s muscles. Since its commercial launch in June 2023, the gene therapy has demonstrated blockbuster potential. Though the therapy was initially approved in the country with a confined label for use in ambulatory DMD patients aged four to five years, it added more than $200 million to Sarepta\u2019s top line in 2023. Last June, the FDA expanded Elevidys\u2019 label to treat all DMD patients aged four years and older, regardless of ambulation status. The approval significantly expands the therapy\u2019s targeted population. In the first nine months of 2024, Sarepta generated more than $400 million, driven by this expanded label. Elevidys has been developed by Sarepta in partnership with pharma big-wig Roche RHHBY. Per a licensing deal signed in 2019, RHHBY has exclusive rights to launch and market Elevidys in ex-U.S. markets. Sarepta started recording royalty revenues from ex-U.S. sales of the therapy in the third quarter of 2024. During the quarter, Sarepta received $9.5 million from Roche as royalty revenues. For 2025, management anticipates net product revenues in the range of $2.9-$3.1 billion, two-thirds of which are expected to come from Elevidys sales. Sarepta\u2019s Pipeline Beyond DMD Encouraging Building on the success of Elevidys, Sarepta is now focusing on expanding its pipeline beyond the DMD space. To reinforce its leadership in gene therapies, management is currently prioritizing the advancement of multiple innovative gene therapies targeting a broader range of muscular dystrophies. Last month, Sarepta reported that it has completed enrolment and dosing in the late-stage EMERGENE study on gene therapy candidate SRP-9003 in patients with limb-girdle muscular dystrophy (LGMD) type 2E/R4 (LGMD2E/R4, or beta sarcoglycanopathy). Data from this study is expected in the first half of 2025. If this data is positive, Sarepta intends to submit a regulatory filing seeking accelerated approval for SRP-9003 in the given indication before this year\u2019s end. Story Continues Sarepta is also evaluating another gene therapy candidate, SRP-6004, in the early-stage NAVIGENE study for treating ambulatory patients living with LGMD type 2B/R2 (LGMD2B/R2, or dysferlinopathy). Last month, Sarepta announced that it has started a clinical study on gene therapy candidate SRP-9004 in LGMD type 2D. Management is also on track to start a clinical study on another gene therapy, SRP-9005, for LGMD type 2C, in early 2025. Both studies are designed to support the FDA\u2019s approval under the accelerated pathway. In November, Sarepta signed a multi-billion dollar deal with Arrowhead Pharmaceuticals ARWR to acquire the latter\u2019s seven pipeline programs. This deal not only complements the company\u2019s existing pipeline of muscular dystrophies but also expands into new indications across the central nervous system and rare pulmonary disorders. In return, SRPT will make an upfront payment of $500 million plus an equity investment of $325 million in Arrowhead\u2019s common stock. ARWR is eligible to receive milestone payments of more than $10 billion as well as royalties on product sales. SRPT\u2019s Dependence on a Single Target Market: A Woe Although Sarepta has four FDA-approved treatments/therapies in its portfolio, all of them are solely focused on one segment \u2014 DMD. The majority of the revenues are generated by Elevidys, which accounted for more than one-third of the company\u2019s total revenues in the first nine months of 2024. Any setback to the therapy\u2019s sales will hurt the company\u2019s prospects. Also, Elevidys sales are cannibalizing the sales of the company\u2019s other three drugs. SRPT Stock Valuation & Estimates The company is trading at a premium to the industry. Going by the price/sales ratio, the stock currently trades at 7.73, trailing 12-month sales value, higher than 1.96 for the industry. Zacks Investment Research Image Source: Zacks Investment Research Estimates for Sarepta Therapeutics\u2019 2024 earnings per share (EPS) have risen from $1.48 to $2.17 in the past 60 days. Over the same timeframe, EPS estimates for 2025 have declined from $10.35 to $10.04. Zacks Investment Research Image Source: Zacks Investment Research How to Play the Stock? Although Sarepta trades at a premium when compared to the industry, we would recommend investors to add this Zacks Rank #3 (Hold) stock to their portfolio, considering Elevidys' strong commercial potential. While the company\u2019s entire commercial portfolio, which targets only one segment, might seem concerning to some investors, management\u2019s plans to diversify beyond DMD seem encouraging. Sarepta\u2019s recently announced $500 million buyback program and the decision to finance the Arrowhead deal with existing cash also highlight management\u2019s confidence in the commercial potential of its currently marketed products and upcoming product launches. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2025-01-06T12:40:00+00:00", "sentiment": {"score": 0.9004163248464465, "confidence": 0.9096659421920776, "probabilities": {"positive": 0.9096659421920776, "negative": 0.009249617345631123, "neutral": 0.08108437061309814}}, "embedding": [-0.11071012914180756, -0.15187598764896393, -0.07480518519878387, -0.053030043840408325, -0.04822712764143944, -0.031337670981884, -0.07748501747846603, 0.30898529291152954, 0.10463497042655945, 0.09800968319177628, -0.08489147573709488, 0.2131822109222412, 0.056951332837343216, 0.022039689123630524, -0.0041138408705592155, 0.045572467148303986, 0.03804366663098335, 0.05668788403272629, -0.0456848107278347, 0.04816625267267227, 0.007641438394784927, 0.0009602028876543045, 0.09098038077354431, 0.039388805627822876, -0.024311145767569542, 0.0011877594515681267, -0.07865488529205322, -0.0307563878595829, -0.13427332043647766, -0.028962086886167526, 0.0367303304374218, 0.021133072674274445, -0.019579030573368073, -0.1310444176197052, -0.06040593981742859, 0.03639847785234451, -0.09987224638462067, 0.06338266283273697, -0.07655221968889236, 0.030055388808250427, 0.0545133501291275, -0.007204282097518444, -0.14504188299179077, -0.07390929758548737, -0.03478441387414932, -0.12159305810928345, -0.08222408592700958, 0.019418831914663315, 0.0629395991563797, 0.1462743878364563, -0.11109898239374161, -0.13535243272781372, 0.06498876214027405, 0.09059342741966248, -0.045446332544088364, -0.01487161498516798, -0.1426994651556015, -0.033633872866630554, 0.04680638387799263, 0.029715342447161674, 0.039301253855228424, -0.009276756085455418, 0.01297061052173376, -0.11425913870334625, 0.15632854402065277, -0.02512398362159729, 0.07046086341142654, -0.03245473653078079, 0.02047773078083992, -0.02707001380622387, 0.158047616481781, -0.004259929992258549, -0.03393189236521721, 0.10329239815473557, -0.07986027747392654, 0.070313461124897, 0.17975744605064392, 0.09203072637319565, 0.20554810762405396, -0.1412135809659958, 0.062390781939029694, 0.028337925672531128, 0.061093319207429886, -0.035873427987098694, -0.025739621371030807, 0.14487627148628235, 0.11400295048952103, 0.13270604610443115, 0.10023702681064606, 0.026544198393821716, 0.084217868745327, -0.004434201866388321, -0.10780452936887741, -0.07121510803699493, 0.006478587165474892, 0.017437253147363663, -0.11438874900341034, 0.015176634304225445, -0.05542556196451187, 0.01669945754110813, 0.08520418405532837, 0.027831485494971275, -0.0201881006360054, -0.0749608725309372, -0.05811089277267456, -0.12274741381406784, 0.0028985561802983284, -0.10700945556163788, -0.0515679195523262, 0.020030438899993896, -0.1047341600060463, 0.01601574942469597, -0.05555969476699829, 0.027727149426937103, -0.07935632765293121, 0.22200074791908264, -0.1124253198504448, 0.013540104031562805, 0.07818649709224701, -0.04261130839586258, 0.06383539736270905, -0.015879403799772263, 0.02633797377347946, -0.06420055031776428, 0.07351042330265045, 0.07043462991714478, -0.17205360531806946, 1.0476377404616674e-32, 0.0012119179591536522, 0.019836274906992912, -0.004557449370622635, -0.035949841141700745, -0.13381963968276978, 0.0010251938365399837, -0.03728697448968887, 0.13458070158958435, -0.12460283190011978, -0.09019064158201218, -0.20033586025238037, -0.040754284709692, 0.01973576843738556, 0.07223211228847504, -0.015049461275339127, -0.05545106530189514, -0.05769854411482811, 0.027404002845287323, -0.0065439967438578606, -0.0525054857134819, 0.02649664878845215, 0.06926265358924866, 0.05342286080121994, 0.09440839290618896, -0.03207847476005554, -0.011584766209125519, -0.09067250043153763, 0.057644493877887726, 0.04419093206524849, 0.06198832020163536, -0.0982133001089096, -0.02903714030981064, 0.04676489531993866, -0.09297941625118256, -0.03303307294845581, -0.12135708332061768, -0.035947080701589584, -0.1185665875673294, 0.09236989915370941, 0.11660962551832199, -0.001025678589940071, 0.09079655259847641, -0.12170985341072083, -0.14727383852005005, -0.01243564859032631, 0.017569061368703842, -0.005202639847993851, -0.09159529209136963, -0.007339377887547016, 0.0011152289807796478, 0.059677015990018845, 0.07624179124832153, -0.0007749442011117935, -0.13970941305160522, -0.08781060576438904, -0.04463382065296173, -0.2288108915090561, -0.16002601385116577, 0.05684451013803482, 0.13555823266506195, 0.04312989115715027, 0.07725948095321655, 0.09304125607013702, 0.01625985838472843, -0.1314420998096466, 0.09418322890996933, 0.009277603588998318, -0.0006627719849348068, -0.04230344295501709, 0.05276231840252876, 0.07008866965770721, -0.15250307321548462, 0.07787735015153885, -0.04947070777416229, 0.1309327781200409, -0.08899855613708496, 0.035865455865859985, 0.14352688193321228, -0.025335092097520828, 0.09267045557498932, -0.010983066633343697, 0.0554683655500412, -0.14545607566833496, 0.14757958054542542, 0.11929437518119812, 0.022924067452549934, -0.012706825509667397, -0.030677855014801025, -0.06324049085378647, -0.07046571373939514, 0.07120712101459503, -0.046336688101291656, -0.0770665854215622, 0.08228857815265656, 0.05696101859211922, -1.0682063936755619e-32, -0.10896989703178406, 0.053454574197530746, 0.014485589228570461, -0.03318564593791962, 0.0251196026802063, 0.019111499190330505, 0.03555842489004135, -0.020430831238627434, 0.06980280578136444, -0.0503520593047142, 0.040345512330532074, 0.005266761872917414, -0.028384678065776825, 0.019049106165766716, 0.001351027749478817, -0.024427175521850586, -0.06400498002767563, -0.035458534955978394, 0.0005669556558132172, -0.03491688519716263, 0.20331567525863647, 0.17765319347381592, -0.03536733239889145, 0.13652873039245605, 0.04687514901161194, -0.010273692198097706, -0.017415504902601242, 0.14365644752979279, 0.08969435095787048, -0.015319609083235264, -0.0997408777475357, 0.06854602694511414, -0.1786184459924698, 0.05720538645982742, -0.054784514009952545, 0.07570777833461761, 0.011468042619526386, -0.048527248203754425, -0.02192886546254158, -0.09600937366485596, 0.07884474098682404, 0.027499355375766754, -0.011391338892281055, 0.1166842058300972, 0.0774165540933609, -0.13165389001369476, 0.06998036801815033, 0.02747628279030323, 0.2565832734107971, -0.0017918809317052364, -0.051211025565862656, 0.001892540603876114, 0.05448499321937561, -0.07690033316612244, -0.0643509030342102, -0.06264326721429825, 0.012829732149839401, 0.025410110130906105, -0.18948152661323547, 0.09309698641300201, -0.03998027369379997, 0.07429160922765732, -0.018505042418837547, 0.018929598852992058, 0.05391004681587219, 0.16877377033233643, 0.10791926085948944, -0.11378715932369232, -0.0018294192850589752, -0.14553767442703247, 0.07428516447544098, -0.08654434233903885, -9.369198232889175e-05, -0.058261044323444366, -0.057293601334095, 0.15274102985858917, -0.021696634590625763, -0.11369096487760544, -0.08082538843154907, -0.06134437769651413, 0.012132445350289345, -0.0028337836265563965, 0.07756774127483368, -0.06903485208749771, -0.018891718238592148, 0.11843603849411011, -0.027143392711877823, -0.048990651965141296, -0.0875609740614891, 0.03581831231713295, -0.08013468980789185, -0.13245341181755066, -0.01644662208855152, 0.05884915962815285, 0.08408662676811218, -1.0051954291157017e-07, 0.14069536328315735, 0.029988698661327362, 0.08751702308654785, -0.03670039400458336, 0.10884353518486023, -0.05352068692445755, -0.005099071189761162, 0.1146012544631958, 0.02123176120221615, 0.22902104258537292, -0.0036869728937745094, 0.16243214905261993, -0.060967326164245605, -0.005443098489195108, -0.02520427294075489, 0.06620291620492935, -0.08941186964511871, 0.15449762344360352, -0.10111713409423828, -0.0724789947271347, -0.008398879319429398, -0.015650469809770584, 0.11509029567241669, -0.10030266642570496, 0.018360430374741554, -0.12324699759483337, 0.021422147750854492, -0.004411935806274414, 0.029505332931876183, -0.011817526072263718, 0.04782143980264664, -0.09786990284919739, 0.08063872158527374, -0.012942462228238583, 0.026187023147940636, -0.20178945362567902, 0.0076234471052885056, 0.12673255801200867, -0.023305296897888184, 0.02565923146903515, 0.007588372565805912, 0.003338475711643696, 0.02569548413157463, 0.040656983852386475, -0.027844462543725967, -0.053710293024778366, -0.17150908708572388, -0.05903477221727371, 0.07768163084983826, -0.08821055293083191, 0.08152729272842407, -0.0802348256111145, 0.003062258008867502, -0.10932392627000809, -0.07899978756904602, 0.09088131785392761, -0.15890029072761536, -0.08399540930986404, -0.06498700380325317, -0.01984279602766037, 0.014461307786405087, -0.15988339483737946, 0.08515852689743042, 0.05782202258706093], "changes": {"1wk": -5.179488353240185}}, {"text": "ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing\u2026 Zacks Small Cap Research Tue, Dec 3, 2024, 2:24 PM 6 min read In This Article: ARWR -5.73% SRPT +0.08% By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced a global license and collaboration agreement with Sarepta Therapeutics (SRPT) in which Arrowhead is set to receive $825 million, consisting of $500 million in cash and $325 million as an equity investment priced at a 35% premium. The agreement covers the following assets: Clinical Stage ARO-DUX4, which is being developed as a treatment for facioscapulohumeral muscular dystrophy type 1 and is currently in a Phase 1/2 clinical trial. ARO-DM1, which is being developed as a treatment for type 1 myotonic dystrophy and is currently dosing patients in a Phase 1/2 clinical trial. ARO-MMP7, which is being developed as a treatment for idiopathic pulmonary fibrosis and is currently dosing patients in a Phase 1/2 clinical trial. ARO-ATXN2, which is being developed as a treatment for spinocerebellar ataxia 2 and is currently in a Phase 1/2 clinical trial. Preclinical Stage ARO-HTT, which is being developed as a treatment for Huntington\u2019s disease ARO-ATXN1, which is being developed as a treatment for spinocerebellar ataxia 1 ARO-ATXN3, which is being developed as a treatment for spinocerebellar ataxia 3 Discovery Stage During the five-year term of the agreement, Sarepta may propose up to six new CNS or muscle targets, with Arrowhead responsible for discovery and preclinical development. Sarepta would then have an exclusive license to the programs and take over responsibility for clinical development and commercialization. The financial terms of the deal are as follows: Arrowhead will receive a $500 million upfront payment along with $325 million from an equity investment by Sarepta at $27.25 per share (a 35% premium to the 30-day volume weighted average price), $250 million payable as $50 per year for five years, and $300 million in near-term payments (likely within the next year), broken up into two separate payments of $100 million and $200 million, tied to enrollment of certain cohorts in the Phase 1 study of ARO-DM1. Arrowhead will be eligible for development milestones of $110 million to $410 million per program, sales milestones of $500 million to $700 million per program, and tiered royalties up to low double digits. The total potential value of the deal is in excess of $11 billion plus royalties. \u2018This deal helps to further validate Arrowheads technology and provides substantial capital that is currently expected to fund operations well into 2028, which could be past multiple commercial launches by Arrowhead and/or its partners. In addition, the company now has a more streamlined pipeline focused more on areas in which Arrowhead wishes to commercialize products on its own, for example in the cardiometabolic space. Story Continues The agreement also stipulates that Arrowhead will manufacture clinical drug supply for all programs covered under the license and collaboration along with commercial drug product for the four programs currently in clinical trials. This will help to utilize the excess manufacturing capacity at the company\u2019s plant and to cover some of its operating costs. Overall, this is a fantastic deal for Arrowhead and should help to alleviate any concerns regarding the company\u2019s liquidity while simultaneously helping to focus attention on a more manageable development pipeline. New Drug Application Submitted for Plozasiran for the Treatment of FCS On November 18, 2024, Arrowhead announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for plozasiran for the treatment of familial chylomicronemia syndrome (FCS). The company plans to submit applications for approval in other jurisdictions in 2025. The NDA is based in part on the successful Phase 3 PALISADE trial, the results of which were recently published in The New England Journal of Medicine ( Watts et al. , 2024 ). The trial met its primary endpoint and showed that treatment with plozasiran led to a median change from baseline of 80% in fasting triglycerides along with a statistically significant 83% reduction in the risk of developing acute pancreatitis compared to placebo. The FDA has 60 days to determine whether to accept the NDA and if accepted we will learn the PDUFA date at that time. Since plozasiran has Breakthrough Therapy designation there is the potential for priority review, which would decrease the total review time to six months from the standard ten months. The decision to grant priority review is made solely at the discretion of the FDA. In preparation for potential approval, the company has indicated that key commercial infrastructure appointments have been made, the commercial field team is in the process of being assembled, and (if approved) the company should be ready to launch in 2025. In addition to FCS, Arrowhead is also developing plozasiran as a treatment for severe hypertriglyceridemia (SHTG), with the Phase 3 SHASTA-3 and SHASTA-4 studies expected to complete enrollment by mid-2025. This would put the final patient visits in mid-2026 and a potential sNDA filing at the end of 2026 or early 2027. The SHASTA-5 trial, which will have a primary outcome of reduction in acute pancreatitis in patients with SHTG and a history of pancreatitis, is expected to initiate soon. During the recent quarterly conference call the company announced that it is putting a potential cardiovascular outcomes trial (CVOT) on hold pending additional capital. Financial Update On November 26, 2023, Arrowhead announced financial results for fiscal year 2024 that ended September 30, 2024. The company reported revenue of $3.6 million for fiscal year 2024 compared to approximately $240.7 million for fiscal year 2023. The revenue in 2023 was primarily related to collaboration agreements with Takeda, GSK, and Amgen. R&D expenses for the year ending September 30, 2024 were approximately $505.9 million compared to $353.2 million for the year ending September 30, 2023. The increase was primarily due to increased candidate costs, salaries, facilities-related expenses, and R&D discovery expenses. G&A expenses for fiscal year 2024 were $98.8 million compared to $92.5 million for fiscal year 2023. The increase was primarily due to increased salaries and professional services partially offset by decreased non-cash stock-based compensation. Arrowhead exited fiscal year 2024 with approximately $681 million in cash, cash equivalents, and investments. As noted above, the collaboration agreement with Sarepta will include $500 million in upfront cash, $325 million as an equity investment, and additional near-term cash of $350 million. This leads to pro forma cash of approximately $1.5 billion and extends the company\u2019s cash runway into 2028. As of November 20, 2024, Arrowhead had approximately 124.4 million shares outstanding and, when factoring in stock options and restricted stock units, a fully diluted share count of approximately 131.3 million. Conclusion The agreement with Sarepta is a great achievement for the company as it helps to strengthen the balance sheet, provides additional validation to the company\u2019s discovery and early-stage capabilities, and helps to streamline the in-house development pipeline where Arrowhead intends to focus its attention. We look forward to the FDA\u2019s decision on whether it will accept the NDA for plozasiran for review as well as the PDUFA date, if accepted. After incorporating the Sarepta agreement into our model our valuation has increased slightly to $73 per share. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to\u00a0receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2024-12-03T11:24:00+00:00", "sentiment": {"score": 0.12888261582702398, "confidence": 0.13772013783454895, "probabilities": {"positive": 0.13772013783454895, "negative": 0.008837522007524967, "neutral": 0.853442370891571}}, "embedding": [-0.09475108981132507, -0.24526149034500122, -0.04999533295631409, -0.05603644624352455, -0.1393098384141922, -0.09043196588754654, 0.014673848636448383, 0.24578867852687836, 0.09580309689044952, 0.12896347045898438, -0.03686019033193588, 0.13912111520767212, -0.008647767826914787, 0.1026240810751915, -0.145653635263443, 0.07028220593929291, -0.0012976592406630516, -0.005466807633638382, -0.006278049200773239, 0.1299421787261963, 0.013124501332640648, 0.06598135083913803, -0.029378840699791908, 0.02892562933266163, 0.015961918979883194, -0.002691822126507759, -0.037164099514484406, 0.012387026101350784, -0.16016346216201782, -0.10351704061031342, 0.051259275525808334, 0.12987159192562103, -0.05684889853000641, -0.15695631504058838, 0.033325325697660446, 0.08111506700515747, -0.13410693407058716, 0.10639701038599014, -0.143907368183136, -0.05630927532911301, 0.05873016640543938, 0.017816077917814255, -0.086632139980793, -0.04792342334985733, 0.01200374960899353, -0.05818398296833038, -0.011024616658687592, 0.06814903020858765, 0.07345099002122879, 0.21072542667388916, -0.10225383937358856, -0.12977541983127594, -0.02125760167837143, 0.05332839488983154, -0.02008473128080368, 0.03992462903261185, -0.1524110734462738, -0.10168080031871796, -0.011547775939106941, 0.07696858048439026, -0.08407638967037201, -0.032062288373708725, -0.060213785618543625, -0.022502467036247253, 0.19765260815620422, 0.08009101450443268, 0.06762000918388367, -0.07838544994592667, -0.03707246854901314, 0.02240070328116417, 0.12491821497678757, -0.11126723885536194, -0.00356281828135252, 0.11846654862165451, -0.04306424409151077, 0.04967585951089859, 0.0630779042840004, 0.10001648962497711, 0.27077552676200867, -0.1415993720293045, 0.06748396158218384, 0.12633423507213593, 0.05988270044326782, -0.052562348544597626, 0.006466958671808243, 0.1457582712173462, 0.0056527890264987946, 0.14617158472537994, 0.08456321060657501, -0.02508123219013214, 0.14597731828689575, -0.01831989735364914, -0.008003764785826206, -0.129959374666214, 0.04772457852959633, -0.012995598837733269, -0.05488145723938942, 0.035907384008169174, -0.005810290575027466, -0.013365417718887329, 0.07231047749519348, -0.11830181628465652, -0.07484810054302216, -0.130456805229187, 0.0461965873837471, -0.05233561992645264, 0.10536706447601318, -0.0852799043059349, 0.02162313647568226, 0.05350847542285919, -0.14785557985305786, 0.005064994562417269, -0.05153070390224457, -0.014538482762873173, -0.023777756839990616, 0.2658059000968933, -0.05178140848875046, -0.10539662837982178, 0.22012323141098022, -0.05557152256369591, 0.004056448116898537, -0.036174528300762177, 0.03549799695611, -0.08469808101654053, -0.002535039559006691, -0.055240847170352936, -0.29060500860214233, 1.3286996152376271e-32, -0.06575697660446167, 0.08777463436126709, -0.03208193928003311, -0.044143982231616974, -0.026085413992404938, -0.06603831052780151, 0.06472326070070267, 0.0037744627334177494, -0.1212620884180069, 0.016616251319646835, -0.18614891171455383, -0.01704832911491394, -0.04323255270719528, 0.14890587329864502, -0.0004872900899499655, -0.09425295889377594, -0.027981499210000038, 0.129179447889328, -0.003233677241951227, -0.07441291213035583, 0.012806087732315063, 0.11117576062679291, 0.03860480338335037, 0.10787781327962875, -0.07127205282449722, 0.0366261750459671, -0.06128973886370659, -0.0020343828946352005, 0.0681254044175148, 0.022388026118278503, -0.044772762805223465, 0.08235355466604233, 0.014753866009414196, -0.097940593957901, -0.0445140041410923, -0.07666323333978653, -0.09516072273254395, -0.06737960875034332, 0.0646660104393959, 0.17873713374137878, 0.02012227475643158, 0.08366571366786957, -0.17552803456783295, -0.12523940205574036, 0.02029205672442913, -0.16944284737110138, -0.014785606414079666, -0.12039490044116974, -0.005258258897811174, -0.01831670105457306, 0.07986970245838165, 0.016024410724639893, -0.0488196462392807, -0.09657655656337738, 0.004459146410226822, -0.009953532367944717, -0.20203205943107605, -0.04500129818916321, 0.1285249888896942, 0.08085259795188904, 0.0033223286736756563, 0.00663337716832757, -0.01802077516913414, 0.0566132590174675, -0.060936518013477325, 0.1805659532546997, -0.008414254523813725, -0.10795065015554428, -0.048857055604457855, 0.05237431079149246, 0.014044282957911491, -0.1603325605392456, 0.14639270305633545, -0.038295160979032516, 0.10165916383266449, -0.12888264656066895, 0.019537197425961494, 0.15484145283699036, 0.058456141501665115, 0.05923110991716385, -0.1035546138882637, 0.08523953706026077, -0.08254960179328918, 0.17989517748355865, 0.012827497906982899, 0.015616758726537228, 0.09564699232578278, -0.01688547432422638, -0.19213742017745972, 0.026868551969528198, 0.17731505632400513, 0.01105498056858778, -0.11937984079122543, 0.06157613545656204, 0.13009193539619446, -1.409593022230989e-32, -0.06453955918550491, 0.052464086562395096, 0.05754472315311432, -0.09015275537967682, -0.1315155029296875, 0.11114896833896637, 0.05795016139745712, -0.030028782784938812, 0.16994266211986542, -0.07018126547336578, -0.019766367971897125, 0.07139256596565247, -0.0819072276353836, 0.00945489201694727, -0.026474028825759888, -0.06201058253645897, -0.03721309453248978, -0.1296154260635376, 0.06785298138856888, -0.030578576028347015, 0.183163583278656, 0.10794761031866074, -0.014681916683912277, 0.10388600826263428, 0.01573723554611206, -0.022273583337664604, 0.00821332260966301, 0.11969155073165894, 0.1488654911518097, 0.07111936062574387, -0.08098861575126648, 0.04885425418615341, -0.2287462055683136, 0.005179787054657936, -0.13937044143676758, 0.0031892098486423492, -0.0167866088449955, -0.04419102519750595, -0.0864730104804039, -0.11587393283843994, 0.12922576069831848, -0.09495631605386734, 0.07891104370355606, -0.0164208821952343, 0.0918954461812973, -0.11916007101535797, 0.08987939357757568, -0.10842679440975189, 0.12373372912406921, -0.15746477246284485, 0.032214391976594925, -0.05748119577765465, 0.08681177347898483, -0.06241375952959061, -0.11554691195487976, -0.009263543412089348, 0.12488532066345215, -0.005556953139603138, -0.06010458990931511, -0.024484749883413315, 0.04628278687596321, 0.06243179365992546, -0.046657171100378036, -0.0216984786093235, 0.0824471116065979, 0.23029954731464386, 0.04933813586831093, -0.13227173686027527, -0.08657760918140411, -0.018070299178361893, -0.06498806923627853, -0.03187769651412964, 0.04845874756574631, -0.08952255547046661, 0.16480353474617004, 0.11451174318790436, -0.04556877538561821, -0.0385361909866333, -0.02343236654996872, -0.08058153092861176, -0.05214823782444, 0.0018381592817604542, -0.07017075270414352, 0.027395857498049736, -0.007629335857927799, -0.019842421635985374, -0.014436276629567146, -0.052803874015808105, -0.012368548661470413, 0.06988605111837387, -0.028843866661190987, -0.08665517717599869, -0.025925246998667717, 0.008757192641496658, -0.009418478235602379, -1.0130500527338882e-07, 0.07957763969898224, 0.04063481464982033, -0.024012546986341476, -0.09460151195526123, 0.007065935991704464, -0.021919995546340942, -0.02023417502641678, 0.12179110944271088, -0.0028467874508351088, 0.12747421860694885, 0.07972017675638199, 0.208732008934021, -0.07747325301170349, 0.00590986292809248, -0.10515367984771729, 0.05556380748748779, -0.11196119338274002, 0.0363173745572567, -0.06369365751743317, -0.06803369522094727, -0.03385283052921295, 0.06116018444299698, 0.009587191976606846, -0.08517864346504211, -0.04614071547985077, -0.024137916043400764, 0.14956530928611755, 0.0966547280550003, -0.06796319782733917, -0.011426551267504692, 0.06916413456201553, -0.012970203533768654, 0.019338900223374367, 0.03767598420381546, -0.006040121894329786, -0.20367014408111572, 0.02504671737551689, 0.13649849593639374, 0.05210269242525101, 0.11551789194345474, -0.03248078003525734, 0.06282300502061844, -0.02122059091925621, 0.00046908482909202576, -0.022102920338511467, 0.01153106801211834, -0.2249296009540558, -0.1205306351184845, 0.11752784252166748, -0.16427604854106903, 0.07606981694698334, 0.09056191891431808, -0.04269614815711975, -0.17008621990680695, -0.07652541995048523, 0.10158352553844452, 0.04045464098453522, -0.11751270294189453, -0.044301483780145645, 0.010368706658482552, 0.08136097341775894, -0.25285136699676514, 0.03426995500922203, 0.052396196871995926], "changes": {"1wk": -10.740311737005666, "1mo": -27.88646161437054}}, {"text": "PREMIUM Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug MT Newswires Mon, Dec 23, 2024, 4:36 PM In This Article: ARWR -5.73% Arrowhead Pharmaceuticals (ARWR) said Monday it dosed the first patients in a phase 1/2a clinical tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2024-12-23T13:36:21+00:00", "sentiment": {"score": 0.04390267562121153, "confidence": 0.05707911029458046, "probabilities": {"positive": 0.05707911029458046, "negative": 0.01317643467336893, "neutral": 0.9297444224357605}}, "embedding": [-0.04920515790581703, -0.21167205274105072, -0.015443616546690464, 0.1993619203567505, 0.07477951794862747, -0.07261724025011063, 0.10294725745916367, 0.160707488656044, -0.005135303363204002, -0.043132483959198, 0.04730738326907158, 0.2192794680595398, -0.02758016623556614, 0.08271098881959915, 0.05550325661897659, -0.07303255796432495, 0.20418623089790344, -0.1473272293806076, 0.1790044754743576, 0.054251428693532944, -0.09402482956647873, 0.01737702265381813, 0.03692285344004631, 0.1699543297290802, -0.026845412328839302, -0.03761553019285202, -0.12548789381980896, 0.005279242526739836, -0.04549916833639145, -0.11038357764482498, 0.057435911148786545, -0.08109616488218307, 0.11317845433950424, -0.021570412442088127, -0.11860938370227814, -0.03583167865872383, -0.08621691912412643, 0.022623000666499138, -0.21325021982192993, 0.10557451844215393, 0.03695530816912651, -0.17651470005512238, -0.12847383320331573, 0.10401410609483719, 0.10310838371515274, -0.09753602743148804, -0.08047765493392944, 0.1431640088558197, 0.007920089177787304, 0.3455534279346466, 0.04608270898461342, -0.1852797269821167, 0.05322551727294922, -0.023467130959033966, 0.08107905089855194, -0.11873793601989746, -0.15227827429771423, -0.12869921326637268, -0.0387221984565258, 0.025167327374219894, -0.15731142461299896, -0.01678195595741272, -0.11108158528804779, 0.07176414877176285, -0.017679380252957344, 0.1912008821964264, 0.032097749412059784, -0.03020836040377617, 0.15335151553153992, 0.00040835572872310877, 0.03390296548604965, -0.037847016006708145, 0.05696755647659302, 0.08651719987392426, -0.013800584711134434, 0.0806463435292244, 0.011689557693898678, -0.08528272807598114, 0.1784789264202118, -0.022298283874988556, -0.07219627499580383, -0.04218783229589462, 0.03236151114106178, 0.07870958745479584, 0.06130082905292511, 0.08049611747264862, -0.06914953142404556, 0.017739472910761833, -0.17222179472446442, -0.11455941945314407, 0.1641472727060318, 0.09026873111724854, -0.03899623826146126, 0.08445199579000473, -0.01737126335501671, -0.021046219393610954, -0.22321051359176636, -0.135056734085083, -0.1476963609457016, 0.029929038137197495, 0.026974055916070938, -0.01159894373267889, -0.06159088760614395, 0.020596405491232872, 0.03764075040817261, -0.13855189085006714, 0.026279713958501816, 0.007640775293111801, -0.03370514512062073, 0.09681523591279984, 0.01004444807767868, -0.009633205831050873, 0.2147751897573471, 0.015379400923848152, -0.043956223875284195, 0.18244411051273346, -0.04826825112104416, 0.007533324882388115, 0.11477820575237274, 0.00873197615146637, -0.04064242169260979, -0.019745884463191032, -0.09489497542381287, -0.20239749550819397, -0.07646863162517548, 0.06021485850214958, -0.06410416960716248, 1.0765690074241055e-32, -0.037490058690309525, -0.025426574051380157, 0.05367085710167885, 0.03296704590320587, 0.04030349478125572, -0.001112592057324946, 0.005028522573411465, -0.13802005350589752, -0.08896150439977646, -0.03712870180606842, -0.08645489811897278, -0.1478879600763321, -0.04238053783774376, 0.2068285495042801, -0.11982156336307526, -0.18324457108974457, -0.009703170508146286, 0.28446322679519653, 0.06278058141469955, 0.011755644343793392, -0.074368916451931, -0.07287029922008514, -0.0926307663321495, -0.03981812298297882, -0.22482307255268097, 0.2511572539806366, -0.015661530196666718, 0.04175611957907677, 0.14362996816635132, 0.10633962601423264, -0.10099996626377106, 0.10340625047683716, -0.03105967678129673, -0.09569714218378067, -0.09432803839445114, -0.07300668954849243, 0.03487921506166458, 0.012739033438265324, -0.09807468205690384, 0.02059272862970829, 0.14660200476646423, 0.11398083716630936, -0.05933313071727753, -0.07979074865579605, -0.0011983191361650825, -0.04022196680307388, -0.15079453587532043, -0.04558565467596054, 0.08952153474092484, -0.04219053313136101, 0.00046685876441188157, 0.07127207517623901, -0.061468880623579025, 0.016859907656908035, 0.08715364336967468, 0.07222779840230942, -0.2403101772069931, -0.032207898795604706, 0.21316349506378174, -0.010521089658141136, 0.1598101556301117, 0.08217794448137283, 0.06205574423074722, -0.008446662686765194, -0.11324147135019302, 0.030400076881051064, -0.11273971199989319, -0.29469990730285645, -0.19615429639816284, 0.1444447785615921, 0.17725516855716705, -0.010788041166961193, 0.040940556675195694, -0.028494372963905334, 0.08040233701467514, 0.0019348344067111611, 0.07898066937923431, 0.06014154106378555, 0.16276635229587555, 0.0048409816808998585, -0.056142743676900864, -0.02921917475759983, 0.06362567842006683, 0.19464966654777527, -0.01835494302213192, -0.04741842672228813, 0.09028526395559311, -0.053779397159814835, -0.13655540347099304, 0.026625119149684906, 0.09355207532644272, -0.025808466598391533, -0.1518753319978714, 0.11682437360286713, 0.037154555320739746, -1.123868328707302e-32, -0.012623368762433529, 0.07679496705532074, 0.04095793515443802, -0.1646081805229187, -0.0931248888373375, 0.05849137902259827, -0.06176697090268135, -0.07845998555421829, 0.3225741386413574, 0.15102282166481018, 0.1351701319217682, 0.16553141176700592, -0.23291905224323273, 0.04143722355365753, 0.1628296971321106, -0.04047558829188347, 0.12072329223155975, -0.21346162259578705, -0.1061270460486412, -0.004339983686804771, 0.08186778426170349, -0.09306362271308899, -0.16189736127853394, 0.1305699497461319, 0.09320106357336044, -0.01643260195851326, 0.2507871985435486, 0.21234308183193207, 0.03867366537451744, -0.09172817319631577, -0.07918206602334976, 0.06005576625466347, -0.15663641691207886, 0.017534950748085976, -0.17796853184700012, 0.0041642687283456326, 0.09411855787038803, -0.0014116796664893627, -0.16251587867736816, -0.1218380257487297, 0.1275957226753235, -0.13148067891597748, -0.16194754838943481, -0.03809291124343872, 0.12267729640007019, -0.13109946250915527, 0.1637934148311615, -0.07038384675979614, 0.22147879004478455, -0.21329791843891144, -0.05218248814344406, -0.015329854562878609, 0.12684349715709686, 0.012521916069090366, -0.034266114234924316, -0.10383669286966324, -0.006622766610234976, -0.06065809354186058, 0.024949653074145317, -0.1775357723236084, -0.008493558503687382, 0.12125032395124435, -0.12346288561820984, -0.056671593338251114, -0.016648009419441223, 0.01104017999023199, 0.1661815494298935, -0.15585823357105255, 0.00337230134755373, -0.01578892581164837, -0.0740959569811821, 7.65269942348823e-05, 0.05464240163564682, -0.066591277718544, 0.06829488277435303, 0.02368217706680298, 0.07541637867689133, 0.05025925114750862, -0.13147760927677155, -0.19781053066253662, 0.05166495963931084, -0.1088697761297226, -0.11345663666725159, -0.029384195804595947, -0.07878032326698303, -0.02151801623404026, 0.07204718887805939, -0.020085999742150307, -0.09263015538454056, 0.21559207141399384, -0.12643945217132568, -0.11117319762706757, -0.27345484495162964, 0.060585055500268936, 0.07374393194913864, -1.0060294641789369e-07, 0.053894780576229095, 0.062353089451789856, 0.016442468389868736, 0.0035183413419872522, -0.12473971396684647, 0.1073545590043068, -0.01053497102111578, 0.06104220449924469, -0.0236054714769125, 0.07590116560459137, 0.059026896953582764, 0.2895243167877197, 0.1779394894838333, -0.03764025494456291, 0.0052274372428655624, 0.1169479712843895, -0.07279989868402481, 0.009607905521988869, -0.06410174071788788, -0.08528713881969452, -0.19721509516239166, 0.10823100060224533, 0.2071671187877655, -0.25646257400512695, -0.03641534969210625, -0.07240601629018784, 0.1033889651298523, 0.07192574441432953, 0.07920387387275696, 0.026046276092529297, -0.07720161974430084, 0.060516729950904846, -0.0605345293879509, 0.0005423775874078274, 0.10234065353870392, -0.08929696679115295, -0.012923765927553177, 0.14670641720294952, 0.08355562388896942, 0.04363769665360451, -0.049088846892118454, -0.05857584625482559, 0.03452377766370773, 0.05018060654401779, -0.04641343280673027, 0.02399330586194992, -0.12633779644966125, 0.011144478805363178, 0.10831782221794128, -0.14372435212135315, -0.01131648849695921, 0.029949991032481194, 0.055431898683309555, -0.13798026740550995, -0.09084026515483856, 0.2231546938419342, -0.01642243005335331, -0.3228256404399872, -0.10797026008367538, -0.013558261096477509, 0.14793823659420013, -0.110255666077137, 0.10373789072036743, 0.0714060440659523], "changes": {"1wk": -4.0000046355814876, "1mo": 0.050634070287776896}}, {"text": "Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Business Wire Mon, Dec 23, 2024, 3:30 PM 3 min read In This Article: ARWR -5.73% -\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue -\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif., December 23, 2024 --( BUSINESS WIRE )--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company\u2019s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a known pathway that signals the body to store fat in adipose tissue. \"ARO-INHBE is an important program for Arrowhead that complements our strategic focus on developing and commercializing important RNAi-based therapies for cardiometabolic diseases. Further, our preclinical studies have yielded promising results for this novel mechanism to reduce body weight and potentially preserve lean muscle mass resulting in improved body composition,\" said James Hamilton, M.D., Chief of Discovery and Translational Medicine at Arrowhead. \"The Phase 1/2 study will evaluate ARO-INHBE as a monotherapy in part 1 and as a combination therapy with tirzepatide in part 2, with both parts enrolling patients with obesity.\" About ARO-INHBE ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. INHBE is a promising genetically validated target in which loss-of-function INHBE variants in humans are associated with improved fat distribution and lower risk of metabolic diseases, such as type 2 diabetes. Activin E acts as a ligand in a pathway that regulates energy homeostasis in adipose tissue. Inhibiting this pathway with investigational ARO-INHBE treatment has the potential to increase lipolysis, and reduce adipose hypertrophy and dysfunction, visceral adiposity, and insulin resistance. About the AROINHBE-1001 Phase 1/2 Study AROINHBE-1001 ( NCT06700538 ) is a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-INHBE in up to 78 adult volunteers with obesity. Part 1 of the study is designed to assess single and multiple doses of ARO-INHBE monotherapy, and Part 2 of the study is designed to assess ARO-INHBE in combination with tirzepatide, a subcutaneously administered GLP-1/GIP receptor co-agonist that has been approved in the United States and the European Union for management of type 2 diabetes mellitus since 2022 and weight management since 2023/2024 respectively. Story Continues About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead\u2019s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com , or follow us on X (formerly Twitter) at @ArrowheadPharma , LinkedIn , Facebook , and Instagram . To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as \"may,\" \"will,\" \"expect,\" \"believe,\" \"anticipate,\" \"hope,\" \"intend,\" \"plan,\" \"project,\" \"could,\" \"estimate,\" \"continue,\" \"target,\" \"forecast\" or \"continue\" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20241223983257/en/ Contacts Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 ir@arrowheadpharma.com Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com Media: LifeSci Communications, LLC Kendy Guarinoni, Ph.D. 724-910-9389 kguarinoni@lifescicomms.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARWR", "date": "2024-12-23T12:30:00+00:00", "sentiment": {"score": 0.6417374555021524, "confidence": 0.6547908782958984, "probabilities": {"positive": 0.6547908782958984, "negative": 0.013053422793745995, "neutral": 0.33215567469596863}}, "embedding": [-0.13295936584472656, -0.09610297530889511, -0.12760013341903687, 0.137209951877594, -0.006718432530760765, -0.07184645533561707, -0.0010495882015675306, 0.08382049947977066, -0.07488425076007843, 0.05034656077623367, -0.16036801040172577, 0.11016235500574112, 0.0004044435918331146, -0.0015789163298904896, 0.053074877709150314, 0.043000251054763794, 0.014224356040358543, 0.012495502829551697, 0.0007343553006649017, 0.0007490183925256133, 0.10446123033761978, -0.04950757697224617, 0.05112754553556442, 0.04547920450568199, -0.18408432602882385, -0.12224143743515015, 0.00419861264526844, 0.004615650046616793, -0.27866631746292114, -0.19867512583732605, 0.07616837322711945, 0.08158572018146515, 0.06721364706754684, -0.0757698267698288, -0.21150700747966766, 0.0813215970993042, -0.05513045936822891, -0.11360498517751694, -0.1913306713104248, -0.07065241038799286, 0.07870234549045563, -0.03971659764647484, -0.05782881751656532, -0.03600110113620758, 0.04110582917928696, -0.07054777443408966, -0.09504809975624084, 0.13715128600597382, 0.03500470146536827, 0.21089836955070496, -0.13910433650016785, -0.11905507743358612, 0.013504266738891602, 0.06279024481773376, 0.11879649758338928, 0.037659041583538055, -0.1607295125722885, -0.10140539705753326, -0.06900529563426971, -0.0521424263715744, 0.09577223658561707, -0.05728057771921158, -0.012197291478514671, 0.05186261981725693, 0.0521358847618103, -0.004315643571317196, 0.026651501655578613, -0.002598439808934927, 0.004356855526566505, 0.030116256326436996, 0.14255329966545105, -0.08802412450313568, -0.08967248350381851, 0.16862070560455322, 0.02575553208589554, 0.15374557673931122, -0.00940045528113842, 0.07403777539730072, 0.13531626760959625, -0.11060360074043274, -0.08149060606956482, 0.09217606484889984, 0.12944650650024414, 0.06085553020238876, -0.046290770173072815, 0.2047816663980484, -0.031182989478111267, 0.151826411485672, -0.1320379227399826, 0.11942866444587708, 0.08530747145414352, 0.04858125001192093, -0.002734237350523472, 0.06781067699193954, 0.002592165023088455, -0.08273553848266602, -0.030710838735103607, -0.02611096017062664, -0.04194674640893936, -0.040415842086076736, 0.06145917624235153, 0.054499171674251556, -0.06583267450332642, -0.02085617557168007, 0.005975073203444481, -0.07081645727157593, 0.09853968024253845, -0.05147920548915863, 0.1065254807472229, 0.11683601140975952, -0.017196981236338615, -0.0794048011302948, 0.0880318433046341, 0.07804640382528305, -0.005827424116432667, 0.1545027196407318, 0.07169008255004883, 0.03733828663825989, 0.038402073085308075, 0.004223073832690716, -0.024481531232595444, 0.020828736945986748, 0.0422009639441967, -0.24528978765010834, -0.04332897812128067, 0.10425638407468796, -0.15128152072429657, 9.259097168358531e-33, -0.06583008170127869, -0.1294276863336563, 0.02966480143368244, 0.051141440868377686, 0.1182820275425911, -0.08400163054466248, -0.08641086518764496, 0.0054673864506185055, -0.09490340948104858, -0.016856223344802856, -0.14623628556728363, -0.11526869982481003, 0.00015064538456499577, 0.23723849654197693, 0.043987710028886795, -0.11389581859111786, -0.018521739169955254, 0.17302657663822174, 0.037466324865818024, -0.04311086982488632, 0.04275692626833916, -0.09334106743335724, -0.0642712414264679, 0.0480048693716526, -0.04981522634625435, 0.21172991394996643, 0.058144956827163696, -0.020477650687098503, -0.03469989448785782, 0.04049341753125191, -0.09986771643161774, 0.047274600714445114, 0.05564916878938675, -0.08190779387950897, -0.10854633152484894, -0.22172021865844727, 0.0065174344927072525, -0.07424522936344147, -0.032898131757974625, 0.14473265409469604, 0.17574705183506012, 0.0009722243994474411, -0.07009640336036682, -0.13859036564826965, 0.04984505474567413, -0.004934854339808226, -0.009926611557602882, 0.005642601288855076, 0.010792751796543598, 0.03701278939843178, 0.12256599217653275, -0.0726616159081459, 0.13372111320495605, -0.10617616027593613, 0.02275547757744789, 0.011953674256801605, -0.2983144521713257, -0.023903291672468185, 0.19390571117401123, 0.015097705647349358, -0.059474483132362366, 0.07495706528425217, 0.047912709414958954, 0.13712607324123383, -0.12874551117420197, 0.020617477595806122, -0.17071938514709473, -0.23913702368736267, -0.23303110897541046, 0.14664915204048157, 0.04675909876823425, -0.041218992322683334, 0.20183664560317993, 0.0404314324259758, 0.1567840576171875, -0.013855749741196632, 0.0044377464801073074, 0.008277839049696922, -0.06813400238752365, 0.026984699070453644, -0.032429806888103485, 0.08270229399204254, -0.020916223526000977, 0.09115254878997803, 0.03994880989193916, -0.03886828571557999, 0.08599790930747986, -0.11772125959396362, -0.02326606586575508, 0.05037498474121094, 0.07566755264997482, 0.015972500666975975, -0.23751118779182434, 0.07416243106126785, 0.06245320290327072, -9.718623624033887e-33, 0.03724416345357895, -0.011382635682821274, 0.016360914334654808, -0.16422079503536224, -0.07358741760253906, 0.21001876890659332, 0.07295434921979904, -0.23897305130958557, 0.21199272572994232, -0.21655768156051636, 0.10066871345043182, -0.02098347619175911, -0.08179354667663574, -0.07040975242853165, 0.1319432258605957, -0.049198947846889496, -0.011340299621224403, -0.14399859309196472, -0.19534572958946228, -0.003010920714586973, 0.09913550317287445, 0.045066818594932556, -0.14395567774772644, 0.016028951853513718, 0.003606081008911133, -0.06496130675077438, 0.05417987331748009, 0.19554731249809265, 0.03115527704358101, 0.05126515403389931, 0.0710999071598053, 0.018216650933027267, -0.23792344331741333, -0.013795940205454826, -0.024030596017837524, -0.010288156569004059, 0.036222681403160095, -0.045598872005939484, -0.07838941365480423, -0.0859663262963295, 0.10841003060340881, -0.013307158835232258, -0.09508251398801804, 0.007145480252802372, 0.03292413800954819, -0.14478574693202972, 0.04664332792162895, -0.12691538035869598, 0.04995717853307724, -0.14840850234031677, 0.06274810433387756, -0.08225087076425552, 0.09134937822818756, 0.04522985965013504, 0.018408767879009247, 1.320522278547287e-05, 0.01934552751481533, -0.005065116100013256, -0.07955053448677063, -0.06317965686321259, -0.08959399908781052, -0.040066927671432495, 0.17518755793571472, 0.0014987001195549965, 0.07858850061893463, 0.22798727452754974, 0.26760125160217285, -0.08689948916435242, -0.01066247746348381, -0.014353765174746513, 0.031595755368471146, -0.09508326649665833, 0.10544911026954651, 0.20928138494491577, 0.1569424271583557, -0.005021288525313139, -0.026998011395335197, -0.13481023907661438, -0.23768800497055054, -0.0638967752456665, -0.11120963096618652, -0.0767216756939888, -0.11011962592601776, -0.12610220909118652, 0.010995103046298027, 0.0891798883676529, -0.07371654361486435, 0.10911301523447037, -0.06935369223356247, 0.16775912046432495, -0.034348662942647934, -0.007299208547919989, -0.1659161001443863, 0.0371377095580101, 0.05413123965263367, -1.0105394210313534e-07, 0.05691467598080635, -0.028465498238801956, 0.02670421451330185, -0.05524807423353195, -0.1284751147031784, 0.020407263189554214, 0.02922140061855316, 0.07789341360330582, 0.027865968644618988, -0.048966098576784134, 0.1954086720943451, 0.23677802085876465, 0.12832266092300415, 0.04101413115859032, 0.08278245478868484, 0.018084213137626648, -0.013438673689961433, 0.04310780391097069, -0.07899942994117737, -0.090223528444767, -0.18762466311454773, 0.036819957196712494, 0.005845341831445694, -0.11331246793270111, 0.03309914842247963, -0.1818673312664032, 0.09610741585493088, 0.05614321678876877, 0.10022258758544922, -0.0472048856317997, 0.025732696056365967, 0.04996872320771217, 0.1110474169254303, 0.0788663700222969, -0.01211877353489399, -0.09342905879020691, 0.14842428267002106, 0.18340197205543518, 0.01171351969242096, 0.18182480335235596, -0.01370983012020588, -0.002533257706090808, 0.01578708365559578, -0.008548028767108917, -0.05921166017651558, -0.07977566868066788, -0.058667197823524475, 0.04964985325932503, 0.05145713686943054, -0.10658498108386993, -0.10928002744913101, 0.1623498499393463, -0.0010912716388702393, -0.05576317384839058, -0.11722815036773682, 0.17046396434307098, -0.11223182082176208, -0.15786460041999817, 0.05118951201438904, -0.05344283580780029, 0.08461154252290726, -0.07697153836488724, 0.11332251876592636, 0.047741178423166275], "changes": {"1wk": -4.0000046355814876, "1mo": 0.050634070287776896}}]